/**
 * Newsletter Articles Data
 * Auto-generated from Exclusive Newsletter Contents CSV
 * DO NOT EDIT MANUALLY - regenerate using generate-newsletter-data.py
 */

export interface NewsletterArticle {
  id: string;
  slug: string;
  title: string;
  subtitle: string;
  description: string;
  category: string;
  relatedPage: string;
  body: string;
  publishedAt: string;
}

export const newsletterArticles: NewsletterArticle[] = [
  {
    id: "insights-into-neurodegenerative-diseases-alzheimers-disease-progression-and-treatments",
    slug: "insights-into-neurodegenerative-diseases-alzheimers-disease-progression-and-treatments",
    title: `Insights into Neurodegenerative Diseases: Alzheimer’s Disease Progression and Treatments`,
    subtitle: `Insights into Neurodegenerative Diseases:`,
    description: `Mouse models expressing human genes implicated in Alzheimer’s disease provided valuable insights into disease progression [1] . In a recent article, researchers used these models to study the...`,
    category: "Neuroscience",
    relatedPage: "/alzheimers-mouse-models",
    body: `<p>[1]</sup>. In a recent article, researchers used these models to study the accumulation of amyloid-beta plaques and tau protein tangles—hallmarks of Alzheimer’s disease.</p><p>The P301S Tau Model: Linking Gut Microbiota and Neurodegeneration</h3><p>One prominent model is the P301S tau transgenic mice, which express the human tau mutations associated with frontotemporal dementia and Alzheimer's. Researchers using this model have found that gut microbiota is critical in tau-mediated neurodegeneration, with the ApoE4 isoform exacerbating the effects, critically, manipulating the gut microbiota through germ-free conditions or antibiotic treatment reduced neurodegeneration in an ApoE-dependent manner. This study underscores the growing importance of the gut-brain axis in Alzheimer’s disease, where dysbiosis can accelerate neurodegeneration, potentially opening new therapeutic avenues targeting microbiota to modulate progression<sup>‍</p><h3>‍</p><p>[3]</sup>.</p><p>APP/PS1 Model: Immune Dysregulation and Neuronal Damage</h3><p>The APP/PS1 model has also provided valuable insights, particularly in identifying the critical role of immune system dysregulation in neurodegeneration. Studies have shown that microglial and T-cell interactions exacerbate neuronal damage, particularly in regions rich in tau pathology, highlighting the potential for immunomodulatory treatments <sup>‍</p><h3>‍</p><p>[5]</sup>.</p><p>Overall, the use of these genetically engineered mouse models in recent years has provided deeper mechanistic insights into AD pathology, focusing on the interplay between genetic risk factors like ApoE4, myelin integrity, and the immune system’s role in neurodegeneration. These models continue to be indispensable in the search for effective disease-modifying therapies.</p>`,
    publishedAt: "2025-01-01",
  },
  {
    id: "article-2-advances-in-metabolic-disorders-research-obesity-and-diabetes",
    slug: "article-2-advances-in-metabolic-disorders-research-obesity-and-diabetes",
    title: `Advances in Metabolic Disorders Research: Obesity and Diabetes`,
    subtitle: `Obesity and Diabetes`,
    description: `Recently developed genetically engineered mouse models have played a pivotal role in advancing our understanding of metabolic diseases, particularly in insulin resistance and obesity. These mouse...`,
    category: "Metabolic",
    relatedPage: "/metabolic-disease-mouse-models",
    body: `<h3>‍</p><p>TET2-deficient mouse models</strong> to explore the relationship between clonal hematopoiesis and chronic liver disease progression, particularly in the context of obesity and insulin resistance. Mice engineered to lack the TET2 gene in hematopoietic cells exhibited more severe liver inflammation and fibrosis when fed a high-fat diet, mirroring conditions such as non-alcoholic steatohepatitis (NASH) in humans. This genetic modification highlighted how the absence of TET2 leads to an enhanced inflammatory response in liver macrophages, contributing to chronic liver damage and fibrosis.</p><p>Gdf15-Null Mice: Understanding Appetite and Energy Expenditure</h3><p>Another crucial genetically engineered model involves <strong>‍</p><h3>‍</p><p>microbiome-engineered mouse models</strong> to assess the impact of gut microbial metabolism on insulin resistance. In these models, mice were engineered to harbor specific gut bacteria associated with insulin sensitivity or resistance. These studies revealed that the presence of insulin-sensitivity-associated bacteria improved host metabolic profiles, while insulin-resistance-associated microbes exacerbated the condition. This provided crucial insights into how microbial carbohydrate metabolism contributes to the development of metabolic syndrome.</p><p>These genetically engineered mouse models, such as those lacking key genes like <strong>GDF15</strong>, or those engineered to harbor specific microbiomes, continue to be instrumental in unraveling the complex mechanisms underlying metabolic diseases. By replicating human-like conditions, they offer a robust platform for testing new therapeutic strategies aimed at addressing the global burden of obesity, insulin resistance, and related metabolic disorders.</p><p id=">‍</p>`,
    publishedAt: "2025-01-01",
  },
  {
    id: "article-3-developments-in-immune-and-infectious-diseases-insights-from-humanized-models",
    slug: "article-3-developments-in-immune-and-infectious-diseases-insights-from-humanized-models",
    title: `Developments in Immune and Infectious Diseases: Insights from humanized models`,
    subtitle: `Insights from humanized models`,
    description: `The ongoing battle against COVID-19 highlighted the need for effective models to study SARS-CoV-2 infection. Researchers developed humanized mouse models expressing the human ACE2 (the receptor for...`,
    category: "Immunology",
    relatedPage: "/humanized-mouse-models",
    body: `<h3>‍</p><h3>‍</p><h3>‍</p><h3>‍</p><p>Klebsiella pneumoniae</em> and <em>‍</p><p id=">These breakthroughs collectively showcase the pivotal role of mouse models in unraveling complex immune processes, host-virus interactions, microbiome studies, and more, guiding vaccine design and informing treatment strategies for infectious diseases.</p>`,
    publishedAt: "2025-01-01",
  },
  {
    id: "article-4-breakthroughs-in-cancer-research-innovations-in-immunotherapy",
    slug: "article-4-breakthroughs-in-cancer-research-innovations-in-immunotherapy",
    title: `Breakthroughs in Cancer Research: Innovations in Immunotherapy`,
    subtitle: `Breakthroughs in Cancer Research:`,
    description: `Mouse Models  CRISPR: Revolutionizing Cancer Immunotherapy   Immunotherapy has transformed cancer treatment, and mouse models have been pivotal in this progress. Recent advancements in cancer...`,
    category: "Oncology",
    relatedPage: "/immuno-oncology-mouse-models",
    body: `<h3>‍</p><p>‍</strong>Immunotherapy has transformed cancer treatment, and mouse models have been pivotal in this progress. Recent advancements in cancer research utilizing genetically modified mouse models have illuminated novel disease mechanisms and furthered the development of therapeutic strategies. CRISPR technology, in particular, has been instrumental in creating more targeted mutations that better replicate human cancer biology.&nbsp;</p><h3>‍</p><h3>‍</p><p>‍</strong>One notable study focused on lung adenocarcinoma, where researchers explored how exposure to fine particulate matter (PM2.5) from air pollution promotes tumorigenesis in EGFR-mutant lung cancers. Using genetically engineered mouse models, such as the <strong>‍</p><h3>‍</p><p>‍</strong>Preclinical research conducted at the University of Pennsylvania has paved the way for safer and more broadly applicable cancer treatments. This groundbreaking study enhanced the effectiveness of CAR T cells in treating various hematologic malignancies while protecting healthy tissues. Researchers explored how CRISPR adenine <strong>‍</p><h3>‍</p><p>‍</strong>Another recent impactful study from MSKCC explored lung adenocarcinoma metastasis and how the immune system regulates the dormancy and reactivation of metastatic cells. Specifically, two mouse models of tumor metastasis, <strong>Foxn1nu</em> athymic nude mice, lacking T cells) and <strong>KrasLSL-G12D/+; Trp53 flox/flox</em> (KP) mice) were used to study cancer progression, focusing on how the STING pathway influences immune surveillance. These models simulated dormancy by allowing disseminated lung adenocarcinoma cells to remain quiescent for extended periods before some reawaken, leading to metastasis. Mouse models provided invaluable insights into immune regulation, genetic factors, and the ability of therapeutic agents to target dormant cancer cells.</p><p>Microbiota Modulate Chemotherapy Response in Pancreatic Cancer</h3><p><strong>humanized gnotobiotic</strong> (germ-free) mice were crucial for studying the role of microbiota in human patients with pancreatic ductal adenocarcinoma, one of the most lethal cancers currently with the poorest prognosis. Mice enabled researchers to investigate how differences in the microbiota from chemotherapy responders and non-responder patients influenced tumor growth and treatment response. The mice were orthotopically injected with PDAC cells and treated with FIRINOX chemotherapy. Mice colonized with microbiota from responding patients showed smaller tumor sizes when treated with chemotherapy, while mice with microbiota from non-responsive patients did not. The study also identified the impact of a microbiota-derived tryptophan metabolite, 3-indole acetic acid (3-IAA), on chemotherapy efficacy in pancreatic cancers.</p><p>Additionally, mouse models were instrumental in evaluating new immune checkpoint inhibitors. Key genetically modified mouse models, such as the <strong>‍</p>`,
    publishedAt: "2025-01-01",
  },
  {
    id: "article-5-advancements-in-gene-editing-technologies-enhancements-in-crispr-cas9",
    slug: "article-5-advancements-in-gene-editing-technologies-enhancements-in-crispr-cas9",
    title: `Advancements in Gene Editing Technologies: Enhancements in CRISPR-Cas9`,
    subtitle: `Advancements in Gene Editing Technologies:`,
    description: `CRISPR: Revolutionizing Research, But at What Cost?  Gene editing technologies have rapidly evolved, with CRISPR-Cas9 at the forefront of these advancements, revolutionizing how researchers study...`,
    category: "Technology",
    relatedPage: "/knockout-mouse-models",
    body: `<h3>‍</p><h3>‍</p><h3>‍</p><h3>‍</p><h3>‍</p><p id=">At the end of 2023, Casgevy, a cell-based gene therapy for treating sickle cell disease and transfusion-dependent beta-thalassemia, became the first FDA-approved CRISPR-based therapy . As gene editing advances, there is growing recognition of the need to balance innovation with safety, especially as clinical trials expand . However, while base and prime editing show great promise for treating genetic disorders, their development is still in the early stages, and much work is needed to optimize these tools for clinical use. One tragic example of this was the fatal outcome of high-dose rAAV9 gene therapy in a patient with Duchenne muscular dystrophy who experienced acute respiratory distress and cardiac arrest. This case highlights the dangers of high-dose AAV therapies, especially in patients with advanced diseases, raising essential questions about the safety of gene therapy delivery systems and the need for safer clinical intervention protocols. CRISPR is already unfolding its tremendous potential for curing human diseases. However, more rigorous preclinical research is needed to ensure its effective and safe clinical applications before moving from experimental to mainstream treatments.</p>`,
    publishedAt: "2025-01-01",
  },
  {
    id: "building-better-floxed-alleles-for-conditional-knockout-mice",
    slug: "building-better-floxed-alleles-for-conditional-knockout-mice",
    title: `Building Better Floxed Alleles for Conditional Knockout Mice`,
    subtitle: `Building Better Floxed Alleles`,
    description: `1. Why floxed alleles still matter  For most therapeutic areas, full germline knockouts are blunt instruments. Developmental lethality, compensation, and systemic effects make it hard to infer...`,
    category: "Technical Guide",
    relatedPage: "/conditional-knockout-mouse-models",
    body: `<h4>1. Why floxed alleles still matter</strong></h4><p>‍<br></strong>For most therapeutic areas, full germline knockouts are blunt instruments. Developmental lethality, compensation, and systemic effects make it hard to infer drug-relevant biology from a simple null. Conditional alleles solve this by allowing <stronghttps://docs.google.com/document/d/1O9pIG9LbR_Wb-LeBSwc5-J3RFJm2D_NRKr0rlDvvSbA/edit?tab=t.0#heading=h.hgxz0ql53y3u">The core architecture has not changed: a <strong>loxP</strong> sites, and <strong>‍</p><phttps://docs.google.com/document/d/1O9pIG9LbR_Wb-LeBSwc5-J3RFJm2D_NRKr0rlDvvSbA/edit?tab=t.0#heading=h.hgxz0ql53y3u"><li>how many orthogonal recombination systems we can combine, and</li><li>For biotech, this translates directly into shorter model timelines, richer mechanism-of-action data, and better design of indication-specific in vivo studies.</p><h4>2. Cre-lox in 2025: from ES cells to one-step alleles</strong></h4><p>‍<br>Classical route.</strong> Historically, floxed alleles were generated by homologous recombination in ES cells, followed by blastocyst injection and breeding. This remains the benchmark for precise allele control, especially for more complex designs, but is slow and infrastructure-heavy. The widely cited review by Gierut et al. remains a solid procedural reference for conditional allele design and breeding strategies <a href="https://docs.google.com/document/d/1O9pIG9LbR_Wb-LeBSwc5-J3RFJm2D_NRKr0rlDvvSbA/edit?tab=t.0#heading=h.hgxz0ql53y3u"><strong>accurate insertion of two loxP sites</strong>. HDR efficiency is modest in zygotes, and mis-integration at either site breaks the allele. Two important optimizations:</p><ul><stronghttps://docs.google.com/document/d/1O9pIG9LbR_Wb-LeBSwc5-J3RFJm2D_NRKr0rlDvvSbA/edit?tab=t.0#heading=h.hgxz0ql53y3u"><strong>Cre and a floxed target in the same plasmid</strong>. This enabled <stronghttps://docs.google.com/document/d/1O9pIG9LbR_Wb-LeBSwc5-J3RFJm2D_NRKr0rlDvvSbA/edit?tab=t.0#heading=h.hgxz0ql53y3u">For a platform or preclinical group, these advances mean you can often move from design to functional conditional line in 1–2 generations instead of 3–4&nbsp; <a href="https://docs.google.com/document/d/1O9pIG9LbR_Wb-LeBSwc5-J3RFJm2D_NRKr0rlDvvSbA/edit?tab=t.0#heading=h.hgxz0ql53y3u"><strong><strong>orthogonal site-specific recombinases</strong> are now standard in the toolkit. Good overviews are provided by Tian et al. (2021) and related recombinase reviews <a href="https://docs.google.com/document/d/1O9pIG9LbR_Wb-LeBSwc5-J3RFJm2D_NRKr0rlDvvSbA/edit?tab=t.0#heading=h.hgxz0ql53y3u"><strong><li>FRT</strong> sites.</li><lihttps://docs.google.com/document/d/1O9pIG9LbR_Wb-LeBSwc5-J3RFJm2D_NRKr0rlDvvSbA/edit?tab=t.0#heading=h.hgxz0ql53y3u">In practice, Flp is often used to remove <stronghttps://docs.google.com/document/d/1O9pIG9LbR_Wb-LeBSwc5-J3RFJm2D_NRKr0rlDvvSbA/edit?tab=t.0#heading=h.hgxz0ql53y3u"><strong><li>rox</strong> sites and is <stronghttps://docs.google.com/document/d/1O9pIG9LbR_Wb-LeBSwc5-J3RFJm2D_NRKr0rlDvvSbA/edit?tab=t.0#heading=h.hgxz0ql53y3u">A growing number of <strong><strong><li>Cre, Flp, and Dre </strong>&nbsp;<a href="https://docs.google.com/document/d/1O9pIG9LbR_Wb-LeBSwc5-J3RFJm2D_NRKr0rlDvvSbA/edit?tab=t.0#heading=h.hgxz0ql53y3u">From a strategy standpoint, this means you can now design <stronghttps://docs.google.com/document/d/1O9pIG9LbR_Wb-LeBSwc5-J3RFJm2D_NRKr0rlDvvSbA/edit?tab=t.0#heading=h.hgxz0ql53y3u"><strong><strong>where</em> and <em><strong><li>CreER stays cytoplasmic until tamoxifen (or 4-OHT) is given, then translocates to the nucleus and excises loxP sites.</li><lihttps://docs.google.com/document/d/1O9pIG9LbR_Wb-LeBSwc5-J3RFJm2D_NRKr0rlDvvSbA/edit?tab=t.0#heading=h.hgxz0ql53y3u"><strong><li>expression</em>, not recombination, but are often wired into Cre.</li><li>doxycycline-controlled Cre expression</strong>, which can be layered on top of tissue-specific promoters to refine timing and dosage of recombination <a href="https://docs.google.com/document/d/1O9pIG9LbR_Wb-LeBSwc5-J3RFJm2D_NRKr0rlDvvSbA/edit?tab=t.0#heading=h.hgxz0ql53y3u"><strong><li>AND / OR logic</strong>: a target might only be activated when both recombinases act, or a stop cassette must be removed by one before the other can trigger a second event&nbsp; <a href="https://docs.google.com/document/d/1O9pIG9LbR_Wb-LeBSwc5-J3RFJm2D_NRKr0rlDvvSbA/edit?tab=t.0#heading=h.hgxz0ql53y3u">This is increasingly used in neuroscience and immunology to target narrowly defined cell subsets (for example, gene X knockout only in cells that express promoter A × promoter B&nbsp; <a href="https://docs.google.com/document/d/1O9pIG9LbR_Wb-LeBSwc5-J3RFJm2D_NRKr0rlDvvSbA/edit?tab=t.0#heading=h.hgxz0ql53y3u"><strong><lihttps://docs.google.com/document/d/1O9pIG9LbR_Wb-LeBSwc5-J3RFJm2D_NRKr0rlDvvSbA/edit?tab=t.0#heading=h.hgxz0ql53y3u">Rapamycin-inducible split-Cre systems allow recombination only when a dimerizing drug is present. These are not yet as widely deployed as CreER but are valuable tools for high-precision mechanistic studies <a href="https://docs.google.com/document/d/1O9pIG9LbR_Wb-LeBSwc5-J3RFJm2D_NRKr0rlDvvSbA/edit?tab=t.0#heading=h.hgxz0ql53y3u"><strong><strong><strong>maternal transmission gives higher or earlier recombination</strong> than paternal. This is due to Cre mRNA/protein already present in the oocyte. It is good practice to test both directions for critical alleles, especially when aiming for full germline deletion <a href="https://docs.google.com/document/d/1O9pIG9LbR_Wb-LeBSwc5-J3RFJm2D_NRKr0rlDvvSbA/edit?tab=t.0#heading=h.hgxz0ql53y3u"><strong>without inheriting Cre</strong>, which avoids extra generations to segregate Cre away. This is an efficient path to convert a floxed allele into a conventional global KO allele once you are done with conditional work <a href="https://docs.google.com/document/d/1O9pIG9LbR_Wb-LeBSwc5-J3RFJm2D_NRKr0rlDvvSbA/edit?tab=t.0#heading=h.hgxz0ql53y3u"><strong>Operational implications:</p><ul>Always include <em>Avoid homozygous Cre unless there is a specific reason.</li><lihttps://docs.google.com/document/d/1O9pIG9LbR_Wb-LeBSwc5-J3RFJm2D_NRKr0rlDvvSbA/edit?tab=t.0#heading=h.hgxz0ql53y3u"><strong><li>functionally essential exons</strong>, not UTRs or exons with robust alternative splicing that may bypass the deletion <a href="https://docs.google.com/document/d/1O9pIG9LbR_Wb-LeBSwc5-J3RFJm2D_NRKr0rlDvvSbA/edit?tab=t.0#heading=h.hgxz0ql53y3u">Remove large selection cassettes with Flp to avoid hypomorphs.</li><li>split the Cre coding sequence with an FRT-flanked cassette</strong> so that Cre is non-functional in ES cells. After germline transmission, crossing to a Flp deleter removes the cassette and restores a functional knock-in Cre that follows the native promoter. This pattern is used in several modern Cre driver lines <a href="https://docs.google.com/document/d/1O9pIG9LbR_Wb-LeBSwc5-J3RFJm2D_NRKr0rlDvvSbA/edit?tab=t.0#heading=h.hgxz0ql53y3u">‍</p>`,
    publishedAt: "2025-01-01",
  },
  {
    id: "conventional-vs-conditional-knockout-mice",
    slug: "conventional-vs-conditional-knockout-mice",
    title: `Conventional Vs. Conditional Knockout Mice`,
    subtitle: `Conventional Vs. Conditional Knockout Mice`,
    description: `Knockout mice were once the cutting edge of genetic engineering for modeling diseases. However traditional conventional knockouts came with an important limitation for biological experimentation....`,
    category: "Technical Guide",
    relatedPage: "/conditional-knockout-mouse-models",
    body: `<p>conventional</strong> <strong>cannot survive until birth</strong> if the knocked-out gene is essential for development. This problem of embryonic lethality means researchers may never get adult mice to study when using a global knockout. Additionally, when a gene is absent throughout the organism’s life, it’s impossible to observe effects that depend on turning the gene off at a specific age. Some phenotypes or disease processes only emerge when a gene stops functioning in adulthood, or only in a particular cell type. To overcome these limitations, <strong>knockouts</strong> were developed to allow researchers to turn the gene off only at specific times or in specific tissues, or even in specific cell subsets. This added precision allows better modeling of human disease conditions, improving the relevance of the mouse model. By controlling <strong>when</strong> a gene is inactivated, scientists can avoid many unintended effects that occur in full-body knockouts and gain more meaningful insights into gene function [1].</p><p><strong>‍</p><p>Cre-loxP recombination system</strong>, which allows precise control over gene deletion. The key is to engineer two mouse lines. In one line, the gene of interest is <strong>loxP sites</strong> in the gene’s introns (non-coding regions). This floxed mouse has a completely normal phenotype until exposed to the Cre enzyme. The second line is a <strong>Cre recombinase</strong> under control of a tissue-specific or inducible promoter. When these two lines are crossed together, the offspring will have the loxP-flanked gene as well as the Cre recombinase. <strong>only in cells where Cre is expressed</strong> [2]. The specificity comes from the promoter driving Cre. For instance, if Cre is expressed only in liver cells, then the gene will be deleted <em>timing</strong> of the gene knockout. Prior to Cre activation, the floxed gene is intact and functions normally . After Cre is activated in the desired cells or at the desired time, it <strong>‍</p><h4>Other recombination systems and combinatorial approaches</strong></h4><p>Beyond the classic Cre‑loxP system, researchers now use multiple site-specific recombinases including Flp‑FRT, Dre‑rox and even Vika‑vox [3], each with its own recognition sites. Using two or more of these in the same mouse model enables <strong>sequential</strong>, and <strong>and</em> marker Y”). This combinatorial approach allows much finer control over <em>when</em> the gene is changed, and <em><li>A triple system (e.g., Cre + Flp + Dre) supports sequential events, conditional activation or deletion of genes in distinct sets of cells or at distinct times.</li><li>For modelling complex diseases, this means you can knockout a gene in one cell type during development, then later delete a second gene in another cell type in adulthood — enabling dissection of cell-autonomous vs non-cell-autonomous effects, temporal phenotypes, or combinatorial gene interactions.</li><li>‍</p><h4>Why Are New Conditional Knockout Techniques So Desirable?</strong></h4><p>From their inception, conditional knockout strategies offered more versatility than conventional knockouts. Researchers can inactivate a gene in a defined cell type or at a chosen developmental stage by selecting the appropriate Cre driver line from various repositories. Before modern genome editing tools, both conventional and conditional alleles were made via laborious ES cell targeting: scientists had to design and insert targeting vectors into ES cells, select correctly modified cells, inject them into blastocysts, and breed chimeric mice. This process could take <strong>CRISPR-Cas9</strong> have dramatically streamlined the creation of certain types of knockout mice. Using CRISPR, researchers can directly inject gene-editing reagents into one-cell zygotes (fertilized eggs), eliminating the time-consuming ES cell step. This means that for simple conditional knockout designs, models can be generated in one step by injecting CRISPR components that insert loxP sites around the target gene. The efficiency and speed are vastly improved: scientists can obtain <strong>more flexible</strong> in design, but are now also <strong id=">faster and easier</strong> to create when compared to traditional methods [5].</p>`,
    publishedAt: "2025-01-01",
  },
  {
    id: "cre-lox-6-facts-you-may-not-know",
    slug: "cre-lox-6-facts-you-may-not-know",
    title: `Cre-Lox: 6 Facts You May Not Know`,
    subtitle: `Cre-Lox:`,
    description: `Conditional knockout (cKO) mice are now basic infrastructure in in vivo biology. The core Cre-lox logic looks simple: cross a tissue-specific Cre line with a floxed allele, get tissue-specific loss...`,
    category: "Technical Guide",
    relatedPage: "/cre-lox-system",
    body: `<p> in vivo</em> biology. The core Cre-lox logic looks simple: cross a tissue-specific Cre line with a floxed allele, get tissue-specific loss of function, and read out phenotype [<a href="https://docs.google.com/document/d/1oStMVUzZrMLokH6-nJS-hk4eOi6T5nTNto_vohZIAq8/edit?tab=t.0#heading=h.iyfy6hbzvve">In practice, the system has many more degrees of freedom. Overlooking them is a good way to misinterpret your data or waste months validating the wrong phenotype. Below are six practical facts that still catch experienced users off guard, with updated context from modern Cre-lox practice.</p><h4>1. You can derive a conventional knockout from a conditional line</strong></h4><p>‍<br></strong>A floxed allele is effectively a “programmable null.” Once you expose the germline to Cre, the floxed exon is deleted in gametes. The resulting offspring carry a constitutive inactivating mutation that segregates as a standard knockout. This has been exploited since early Cre-mediated gene repair and knockout work in mice [<a href="https://docs.google.com/document/d/1oStMVUzZrMLokH6-nJS-hk4eOi6T5nTNto_vohZIAq8/edit?tab=t.0#heading=h.iyfy6hbzvve"><li>Cross to a germline Cre driver (e.g., EIIa-Cre, Sox2-Cre, various knock-in Cre lines) to generate a global null.&nbsp;&nbsp;</li><li>For drug discovery and mechanism-of-action work, you get both a clean “maximal inhibition” model (germline null) and temporal- or tissue-specific models (cKOs) from one design [<a href="https://docs.google.com/document/d/1oStMVUzZrMLokH6-nJS-hk4eOi6T5nTNto_vohZIAq8/edit?tab=t.0#heading=h.iyfy6hbzvve"><strong><stronghttps://docs.google.com/document/d/1oStMVUzZrMLokH6-nJS-hk4eOi6T5nTNto_vohZIAq8/edit?tab=t.0#heading=h.iyfy6hbzvve">Uncontrolled inversion is not very useful, so modern designs use pairs of incompatible mutant lox sites (e.g., lox2272, lox5171) to create <emhttps://docs.google.com/document/d/1oStMVUzZrMLokH6-nJS-hk4eOi6T5nTNto_vohZIAq8/edit?tab=t.0#heading=h.iyfy6hbzvve"><li>Sequential recombination events invert the cassette and then lock it so it cannot flip back.&nbsp;&nbsp;</li></ul><p><li>Inversion-based traps (XTR and related designs) that simultaneously disrupt an endogenous gene and express a fluorescent reporter, point mutation, or human cDNA - with the option to restore wild-type expression via a second recombinase such as Flp.&nbsp;&nbsp;</li></ul><phttps://docs.google.com/document/d/1oStMVUzZrMLokH6-nJS-hk4eOi6T5nTNto_vohZIAq8/edit?tab=t.0#heading=h.iyfy6hbzvve"><strong><strong>Large conditional resources such as the EUCOMM/IKMC/IMPC cKO library showed that loxP placement matters. loxP insertions in the first intron or near regulatory elements can mis-regulate expression even before Cre exposure [<a href="https://docs.google.com/document/d/1oStMVUzZrMLokH6-nJS-hk4eOi6T5nTNto_vohZIAq8/edit?tab=t.0#heading=h.iyfy6hbzvve">Key points for modern designs:</p><ul>Introns are not “junk.” First introns frequently carry enhancers and regulatory elements. Disrupting these can yield hypomorphic alleles at baseline [<a href="https://docs.google.com/document/d/1oStMVUzZrMLokH6-nJS-hk4eOi6T5nTNto_vohZIAq8/edit?tab=t.0#heading=h.iyfy6hbzvve">Splice sites are sensitive. Even a 34-bp loxP sequence can perturb splicing if too close to splice donor/acceptor or branch points. Current artificial-intron design guides recommend placing recombinase-regulated introns away from critical splicing motifs and in exons where disruption gives a clear loss-of-function [<a href="https://docs.google.com/document/d/1oStMVUzZrMLokH6-nJS-hk4eOi6T5nTNto_vohZIAq8/edit?tab=t.0#heading=h.iyfy6hbzvve">Short conditional introns such as SCON and related rAIs are now used to build cKOs by inserting a compact, Cre-sensitive intron that becomes nonfunctional after recombination. They make one-step CRISPR generation of floxed alleles in zygotes practical, but still require careful exon and insertion-site choice [<a href="https://docs.google.com/document/d/1oStMVUzZrMLokH6-nJS-hk4eOi6T5nTNto_vohZIAq8/edit?tab=t.0#heading=h.iyfy6hbzvve">Practical rule of thumb:</p><ul>Avoid known regulatory regions and conserved elements.</li><lihttps://docs.google.com/document/d/1oStMVUzZrMLokH6-nJS-hk4eOi6T5nTNto_vohZIAq8/edit?tab=t.0#heading=h.iyfy6hbzvve"><strong><stronghttps://docs.google.com/document/d/1oStMVUzZrMLokH6-nJS-hk4eOi6T5nTNto_vohZIAq8/edit?tab=t.0#heading=h.iyfy6hbzvve"><li>Mosaic patterns within the intended tissue.</li><li>Inducible CreERT/CreERT2 lines are not immune. Tamoxifen-independent “leak” recombination and tissue-specific differences in tamoxifen metabolism can create background recombination even without induction or at lower doses than expected [<a href="https://docs.google.com/document/d/1oStMVUzZrMLokH6-nJS-hk4eOi6T5nTNto_vohZIAq8/edit?tab=t.0#heading=h.iyfy6hbzvve"><li>For any new Cre x floxed allele combination, empirically map recombination with a reporter or allele-specific PCR in the tissues relevant to your question, across the age and conditions you care about.</li><li><strong><strong>Classical chromosome engineering work in mice showed:</p><ul>Cre-mediated recombination between loxP sites on the same chromosome drops as genetic distance increases, although efficient recombination can still occur over tens of kilobases if chromatin is permissive [<a href="https://docs.google.com/document/d/1oStMVUzZrMLokH6-nJS-hk4eOi6T5nTNto_vohZIAq8/edit?tab=t.0#heading=h.iyfy6hbzvve">Nevertheless, high-efficiency recombination can still occur over tens of kilobases if chromatin context is permissive. For example, efficient deletion has been reported with loxP sites 20+ kb apart [<a href="https://docs.google.com/document/d/1oStMVUzZrMLokH6-nJS-hk4eOi6T5nTNto_vohZIAq8/edit?tab=t.0#heading=h.iyfy6hbzvve">More recent studies in mammalian cells have pushed this further, showing substantial recombination frequencies with loxP sites separated by up to ~1.8 Mb, again in a context-dependent manner.&nbsp;&nbsp;</p><p><li>A generic Cre reporter knocked into a safe-harbor locus will usually overestimate deletion efficiency at your gene of interest. The reporter construct is in a different genomic context and often has a simpler structure than your floxed gene.&nbsp;&nbsp;</li></ul><p><strong><strong>Several features conspire here:</p><ul>Many Cre drivers are expressed in multiple tissues at very different levels. A binary reporter (on/off) is often triggered at low Cre levels, so it tells you <em>how much</em> or for how long. That can be sufficient to recombine a high-efficiency reporter but not a more complex or chromatin-shielded floxed allele [<a href="https://docs.google.com/document/d/1oStMVUzZrMLokH6-nJS-hk4eOi6T5nTNto_vohZIAq8/edit?tab=t.0#heading=h.iyfy6hbzvve">Mosaic recombination is common even in ubiquitous or early-acting lines, leading to animals where only a subset of target cells are actually knocked out [<a href="https://docs.google.com/document/d/1oStMVUzZrMLokH6-nJS-hk4eOi6T5nTNto_vohZIAq8/edit?tab=t.0#heading=h.iyfy6hbzvve">Conditional alleles generated by different methods (ES cell targeting vs CRISPR, standard vs artificial intron designs) can have systematically different sensitivities to the same Cre driver [<a href="https://docs.google.com/document/d/1oStMVUzZrMLokH6-nJS-hk4eOi6T5nTNto_vohZIAq8/edit?tab=t.0#heading=h.iyfy6hbzvve">For new conditional lines, modern groups increasingly:</p><ul>Build in conditional reporters (e.g., inversion-based fluorescent traps or SCON-style cassettes) that light up only after successful recombination at the endogenous locus.&nbsp;&nbsp;</li><li>Consider alternative recombinases or engineered Cre variants with improved specificity and activity when standard drivers underperform.&nbsp;&nbsp;</li></ul>`,
    publishedAt: "2025-01-01",
  },
  {
    id: "how-humanized-mouse-models-are-transforming-pre-clinical-r-d",
    slug: "how-humanized-mouse-models-are-transforming-pre-clinical-r-d",
    title: `How Humanized Mouse Models Are Transforming Pre-clinical R&D`,
    subtitle: `Harnessing Humanized Mouse Models - Part 1`,
    description: `Harnessing Humanized Mouse Models  Preclinical Disease Models That Deliver Better Predictive Power  The accelerating costs of biomedical RD and the high failure rates of clinical trials have...`,
    category: "Immunology",
    relatedPage: "/humanized-mouse-models",
    body: `<h1>‍</p><h3>Preclinical Disease Models That Deliver Better Predictive Power</strong></h3><p>The accelerating costs of biomedical R&amp;D and the high failure rates of clinical trials have underscored a critical need: better <strong><em>‍</p><p>Part 1</strong>, we examine<em>‍</p><h3>Introduction – The Translational Gap</strong></h3><figurew-richtext-figure-type-image w-richtext-align-center" data-rt-type="image" data-rt-align="center"><divhttps://cdn.prod.website-files.com/665dc660af52559c0ed6ec8b/68c2edb92c6228958faa662e_Screenshot%202025-09-11%20at%2011.41.06%E2%80%AFAM.png" loading="lazy" alt="__wf_reserved_inherit" width="auto" height="auto"><strong>The newest generations of humanized strains go far beyond simple transgenesis. Sophisticated HLA class I and II knock-ins reproduce allele-specific antigen presentation, enabling true human-restricted T-cell responses for vaccines and immuno-oncology work [1, 3]. Multi-cytokine platforms such as MISTRG and NSG-SGM3 express human growth factors from their endogenous loci, fostering robust myeloid and lymphoid lineages that reveal cytokine-driven toxicities invisible in standard models [2, 5, 6]. Dual-humanization approaches layer a functional human liver onto an autologous immune system, creating single-animal testbeds for pharmacokinetics, immune-mediated hepatotoxicity and cross-organ crosstalk [8]. Together, these capabilities tighten decision-making at every stage—target discovery, lead optimization, IND-enabling safety and even patient-stratified “clinical trials in mice.” Regulatory agencies are increasingly receptive to data generated in these systems, particularly for cell- and gene-therapy (CGT) assets and rare-disease programmes where traditional comparators are lacking.</p><p><strong>At their core, humanized mice rely on profound immunodeficiency (e.g., Rag-/- Il2rg-/-) so that engrafted human cells are not rejected. Knock-in engineering then installs human cytokines or HLA loci at the native mouse sites, ensuring physiological expression levels and correct spatiotemporal control. Finally, researchers transplant human CD34⁺ haematopoietic stem cells, primary hepatocytes or organ tissues, allowing these grafts to mature within a living organism and integrate into systemic networks. Conditioning regimens such as sub-lethal irradiation or busulfan open marrow niches, while selective pressure in FAH-/- livers drives efficient hepatocyte takeover. The result is a chimeric animal that can mount human-like immune responses, metabolise xenobiotics with human enzymes, or host tissue-specific pathogens—all within one experimental platform.</p><p class="w-richtext-figure-type-image w-richtext-align-center" data-rt-type="image" data-rt-align="center"><divhttps://cdn.prod.website-files.com/665dc660af52559c0ed6ec8b/68c2ee0a564f8d82274c1831_Screenshot%202025-09-11%20at%2011.42.37%E2%80%AFAM.png" loading="lazy" alt="__wf_reserved_inherit" width="auto" height="auto">‍</p><h3>Real-World Impact</strong></h3><figurew-richtext-figure-type-image w-richtext-align-center" data-rt-type="image" data-rt-align="center"><divhttps://cdn.prod.website-files.com/665dc660af52559c0ed6ec8b/68c2ee3f33927fa9be16bd6a_Screenshot%202025-09-11%20at%2011.43.32%E2%80%AFAM.png" loading="lazy" alt="__wf_reserved_inherit" width="auto" height="auto">‍</p><h3>Take-Away Message</strong></h3><p>mission-critical infrastructure</strong>. By embedding authentic human immunity, metabolism and organ physiology into a living animal, they close the translational gap, reduce late-stage failure risk and unlock modalities—CGT, mRNA vaccines, oncolytic viruses—that conventional models cannot handle. For any pipeline that depends on human-specific biology, integrating humanized models is now a competitive necessity, not a luxury.</p><p><strong>In Part 2, we’ll dive into the immune-specific innovations that are redefining immuno-oncology and vaccine development. Learn how these breakthroughs are enabling researchers to study human immune responses with unprecedented accuracy.</p><p id=">‍</p>`,
    publishedAt: "2025-01-01",
  },
  {
    id: "how-to-obtain-a-conditional-knockout",
    slug: "how-to-obtain-a-conditional-knockout",
    title: `How To Obtain A Conditional Knockout`,
    subtitle: `How To Obtain A Conditional Knockout`,
    description: `Introduction  Conditional knockout mice have become indispensable tools in preclinical research. Since their introduction in the mid-90s, they have enabled researchers to inactivate genes in specific...`,
    category: "Technical Guide",
    relatedPage: "/conditional-knockout-mouse-models",
    body: `<h3>‍</p><p>indispensable tools</strong> in preclinical research. Since their introduction in the mid-90s, they have enabled researchers to <stronghttps://docs.google.com/document/d/1J3hxylPWcmvCE98DmR75N5ou8EefPFVYVx5QfhIRTi0/edit?tab=t.0#heading=h.c6viy04cv4s5">Cre</em> recombinase and <em>with spatial and temporal precision </strong><a href="https://docs.google.com/document/d/1J3hxylPWcmvCE98DmR75N5ou8EefPFVYVx5QfhIRTi0/edit?tab=t.0#heading=h.c6viy04cv4s5">‍</p><h3>‍</p><p>site-specific recombination</strong> technology based on an enzyme called Cre recombinase that recognizes short DNA sequences called loxP sites <a href="https://docs.google.com/document/d/1J3hxylPWcmvCE98DmR75N5ou8EefPFVYVx5QfhIRTi0/edit?tab=t.0#heading=h.c6viy04cv4s5">two loxP sites</strong> flanking a critical exon (“<em>knocking out</strong> the gene’s function in that cell. Importantly, if no Cre is present, the floxed gene remains intact and normal in all other cells.</p><p>Key components and steps in generating a floxed mouse model:</h3><ol><strong><strong><strong>tissue-specific promoter</strong> (so it’s only active in certain cell types <a href="https://docs.google.com/document/d/1J3hxylPWcmvCE98DmR75N5ou8EefPFVYVx5QfhIRTi0/edit?tab=t.0#heading=h.c6viy04cv4s5">inducible Cre system</strong> (activated by a drug at a chosen time <a href="https://docs.google.com/document/d/1J3hxylPWcmvCE98DmR75N5ou8EefPFVYVx5QfhIRTi0/edit?tab=t.0#heading=h.c6viy04cv4s5">recombines</strong> them, excising the intervening DNA. The result is a <strong>This strategy provides a high degree of control. Researchers can, for example, knock out a gene only in the liver, or only in neurons after the animal reaches adulthood. The specificity comes from restricting where/when Cre is active. Notably, the Cre-lox mechanism is versatile – if loxP sites are oriented appropriately, Cre can also invert or translocate DNA segments – but excision of a floxed exon (to create a null allele) is the most common application in conditional knockouts.</p><p>Controlled Gene Inactivation: Tissue-Specific and Inducible Cre Systems</h3><p>“Conditional” knockout refers to the ability to control <em>when</em> the gene is disabled. This is achieved by regulating Cre. A vast array of <strong>‍</p><p>temporal control</strong> of gene knockout is possible using inducible Cre systems. The most widely used approach is the tamoxifen-inducible Cre, in which Cre is fused to a modified estrogen receptor (Cre-ER). The fusion protein remains inactive in the cytoplasm until the drug tamoxifen is administered, upon which Cre translocates to the nucleus and triggers recombination <a href="https://docs.google.com/document/d/1J3hxylPWcmvCE98DmR75N5ou8EefPFVYVx5QfhIRTi0/edit?tab=t.0#heading=h.c6viy04cv4s5"https://docs.google.com/document/d/1J3hxylPWcmvCE98DmR75N5ou8EefPFVYVx5QfhIRTi0/edit?tab=t.0#heading=h.c6viy04cv4s5">fine-tuned control over gene inactivation</strong>. Such control is critical when studying genes essential for development or other vital processes, where a conventional knockout would be lethal or confounding.</p><p>Advances and Alternatives: Beyond the Classic Cre-Lox</h3><p>The Cre-lox system has proven to be a robust, reliable platform — often described as a “tried-and-true” method — but researchers have also developed complementary tools to expand our genetic engineering toolkit. One prominent alternative is the FLP-FRT recombination system, which operates on a similar principle using Flp recombinase (from yeast) and FRT sites. FLP-FRT was discovered around the same time as Cre-lox, but the original Flp enzyme was less efficient in mammalian cells (being temperature-sensitive). An enhanced version, FLPe, was engineered to be more thermostable and active in mice, and a codon-optimized <stronghttps://docs.google.com/document/d/1J3hxylPWcmvCE98DmR75N5ou8EefPFVYVx5QfhIRTi0/edit?tab=t.0#heading=h.c6viy04cv4s5">‍</p><p>e</strong> ϕC integrase (from bacteriophage ϕC31) mediates recombination between attB/attP sites and, unlike Cre or Flp, performs unidirectional DNA integration useful for certain genomic insertions <a href="https://docs.google.com/document/d/1J3hxylPWcmvCE98DmR75N5ou8EefPFVYVx5QfhIRTi0/edit?tab=t.0#heading=h.c6viy04cv4s5"https://docs.google.com/document/d/1J3hxylPWcmvCE98DmR75N5ou8EefPFVYVx5QfhIRTi0/edit?tab=t.0#heading=h.c6viy04cv4s5">both</em> recombinases undergo a genetic change – adding an extra layer of specificity in labeling or deleting genes in cell sub-subtypes <a href="https://docs.google.com/document/d/1J3hxylPWcmvCE98DmR75N5ou8EefPFVYVx5QfhIRTi0/edit?tab=t.0#heading=h.c6viy04cv4s5">‍</p><p>both</em> Cre-lox and CRISPR are now considered fundamental tools for gene knockout studies <a href="https://docs.google.com/document/d/1J3hxylPWcmvCE98DmR75N5ou8EefPFVYVx5QfhIRTi0/edit?tab=t.0#heading=h.c6viy04cv4s5">‍</p><h3>‍</p><phttps://docs.google.com/document/d/1J3hxylPWcmvCE98DmR75N5ou8EefPFVYVx5QfhIRTi0/edit?tab=t.0#heading=h.c6viy04cv4s5">‍</p><p>Conditional knockout technology remains an essential platform for in vivo research</strong>, combining proven reliability with exquisite control. By partnering with experts in conditional model generation, biotech innovators can efficiently unravel gene functions and disease mechanisms, de-risk targets, and accelerate their path to breakthroughs, all while relying on the formidable precision of Cre-lox and its modern enhancements.</p>`,
    publishedAt: "2025-01-01",
  },
  {
    id: "how-a-knockout-mouse-is-made",
    slug: "how-a-knockout-mouse-is-made",
    title: `How a Knockout Mouse Is Made`,
    subtitle: ``,
    description: `Understanding how knockout mice are generated is essential for biomedical researchers. Recent advances in genome editing have dramatically streamlined this process, enabling labs to create knockout...`,
    category: "Technical Guide",
    relatedPage: "/custom-mouse-models",
    body: `<p>Creating knockout mice involves different strategies depending on research goals. Traditional homologous recombination in embryonic stem (ES) cells and the CRISPR/Cas9 system are the primary methods. Advances in the CRISPR toolbox—including base and prime editors—offer additional options for precise edits. Each method has unique advantages: ES cell targeting allows complex insertions, while CRISPR enables rapid, multiplex editing.</p><p>What is a knockout mouse?</h3><p>A knockout mouse is a genetically engineered animal with an inactivated gene. Researchers disrupt genes to study effects on development, physiology, or disease. Knockout mice mimic human disorders and reveal gene functions. CRISPR/Cas9 has made creating such models routine, expanding their use in biomedical research.</p><p>Which techniques are commonly used for gene knockout in mice?</h3><p>Gene Targeting – A Method for Creating a Knockout Mouse Using ES Cells</h5><p>Gene targeting via homologous recombination in ES cells remains robust. Researchers design a targeting vector with homology arms flanking the gene, inserting selection markers like neomycin resistance to disrupt the wild-type sequence. The plasmid is electroporated into ES cells, where recombination machinery replaces the native exon with the engineered sequence. Traditional ES cell methods remain effective for complex knockouts.</p><p><strong><li><li2">Identifying Cells that Contain the Knockout Gene</li></ol><ul>Cells undergo drug selection and PCR or sequencing-based screening to identify correctly targeted clones. Verified clones are advanced to embryo injection.</li></ul><ol start="3">Generating a Chimeric Mouse</li></ol><ul>Verified ES cells are injected into blastocysts, creating chimeric offspring visibly identifiable by mixed coat colors .</li></ul><ol start="4">Breeding Chimeric Mice</li></ol><ul>Chimeras are bred with wild-type mice to establish germline transmission. Confirmed via genotyping, offspring carrying the knockout allele are used to create homozygous knockout lines.</li><li>Utilizing CRISPR/Cas9 Technology to Make a Knockout Mouse Model</h3><p>The CRISPR/Cas9 system uses guide RNA to direct Cas9 endonuclease to specific DNA sites. Delivered as ribonucleoprotein complexes into a zygote, Cas9 introduces double-strand breaks, repaired by non-homologous end joining, resulting in gene-disrupting mutations. Modern protocols use high-fidelity Cas9 variants and chemically modified sgRNAs to minimize off-target effects. Given the high efficiency of the CRISPR/Cas9 system in introducing DNA breaks and in consequence inducing targeted recombination, this makes CRISPR a faster method for certain types of knockout mouse generation.</p><p>Knockout Mice Using CRISPR:</h5><ol><strong><li2"><strong><li3"><strong><li>‍</p><h3>‍</p><h3>‍</p><p>Validation</h3><p>Comprehensive validation of the genome-edited model includes sequencing both the mutation site and flanking regions to confirm the intended edit and to rule out potential off-target effects, such as large deletions or rearrangements that may occur during CRISPR editing. Once genetic accuracy is established, functional assays—such as RT-qPCR, Western blotting, or phenotypic assessments—are conducted to verify that the targeted gene has been effectively disrupted and that its expression is absent or significantly diminished.</p><p>How Knockout Mice Differ from Knockin Mice</h3><p>Although both knockout and knockin mice are genetically engineered models, they serve distinct purposes in functional genomics. Knockout mice are created by deleting or disrupting a gene, rendering it non-functional. This null mutation is used to investigate the physiological roles of specific genes and their involvement in disease processes.</p>`,
    publishedAt: "2025-01-01",
  },
  {
    id: "inside-the-humanized-mouse-engineering-the-human-immune-system",
    slug: "inside-the-humanized-mouse-engineering-the-human-immune-system",
    title: `Inside the Humanized Mouse: Engineering the Human Immune System`,
    subtitle: `Harnessing Humanized Mouse Models - Part 2`,
    description: `Harnessing Humanized Mouse Models  Preclinical Disease Models That Deliver Better Predictive Power  In Part 1 of this series, we explored the translational gap that continues to undermine drug...`,
    category: "Immunology",
    relatedPage: "/humanized-mouse-models",
    body: `<h3>‍</p><h4>Preclinical Disease Models That Deliver Better Predictive Power</strong></h4><p>In Part 1 of this series, we explored the translational gap that continues to undermine drug development and clinical success, highlighting how humanized mouse models have emerged as a pivotal solution. These sophisticated models, by more accurately reflecting human biology, offer researchers and biotech developers a powerful tool to de-risk therapeutic strategies and align preclinical research with clinical outcomes. In this second piece, we shift the focus inside the immune system of the humanized mouse to uncover the technological breakthroughs that have made these models indispensable for immunology, vaccine development, and autoimmune disease research.</p><p><strong>‍</p><phttps://docs.google.com/document/d/1uDOEakSlg_vyeHuo0wNznaBSJ1ctYa6znOfodH8wCTU/edit?tab=t.0#heading=h.4u1tlx2nib45">‍</p><phttps://docs.google.com/document/d/1uDOEakSlg_vyeHuo0wNznaBSJ1ctYa6znOfodH8wCTU/edit?tab=t.0#heading=h.4u1tlx2nib45">‍</p><phttps://docs.google.com/document/d/1uDOEakSlg_vyeHuo0wNznaBSJ1ctYa6znOfodH8wCTU/edit?tab=t.0#heading=h.4u1tlx2nib45">‍</p><phttps://docs.google.com/document/d/1uDOEakSlg_vyeHuo0wNznaBSJ1ctYa6znOfodH8wCTU/edit?tab=t.0#heading=h.4u1tlx2nib45">‍</p><phttps://docs.google.com/document/d/1uDOEakSlg_vyeHuo0wNznaBSJ1ctYa6znOfodH8wCTU/edit?tab=t.0#heading=h.4u1tlx2nib45">‍</p><p><strong>‍</p><phttps://www.genetargeting.com/exclusive-newsletter-content/how-humanized-mouse-models-are-transforming-pre-clinical-r-d">Part 1:&nbsp; How Humanized Mouse Models Are Transforming Preclinical R&amp;D</strong>].</a></p><p><strong>‍</p><p>Part 3: Modeling Complexity – Multi-Cytokine and Multi-Organ Humanization</strong>].</p>`,
    publishedAt: "2025-01-01",
  },
  {
    id: "knock-in-mice-vs-transgenic-mice-what-you-need-to-know",
    slug: "knock-in-mice-vs-transgenic-mice-what-you-need-to-know",
    title: `Knock-In Mice vs. Transgenic Mice: What You Need to Know`,
    subtitle: `Knock-In Mice vs. Transgenic Mice:`,
    description: `Knock-in and transgenic mice are foundational tools in biomedical research, yet their strategic differences drive distinct experimental outcomes and value. Both play key roles and accelerated our...`,
    category: "Selection Guide",
    relatedPage: "/knockin-mouse-models",
    body: `<h3>‍</p><ul><strong><strong class="w-richtext-figure-type-image w-richtext-align-center" data-rt-type="image" data-rt-align="center"><divhttps://cdn.prod.website-files.com/665dc660af52559c0ed6ec8b/691bc2d1c5744cf1133b12c6_Screenshot%202025-11-17%20at%207.50.08%E2%80%AFPM.png" loading="lazy" alt="__wf_reserved_inherit" width="auto" height="auto">‍</p><h3>‍</p><ul><strong><strong>Knock-ins typically add or replace sequences at a defined locus. They can also be designed to inactivate an allele by inserting stop cassettes, frameshifts, or recombinase-dependent traps. Transgenics are not inherently unpredictable; classic random lines can vary, yet safe-harbor targeting at Rosa26 or H11 yields stable single-copy expression with fewer position effects [5].</p><p>Modern Advances and Value</h3><p>In combination with modern genome engineering, knock-in and transgenic strategies now operate as a flexible toolkit that can be layered to answer mechanistic and translational questions with precision. Inducible and conditional systems such as Cre, Flp, Dre, and ligand-responsive variants like CreERT2 or Tet enable tissue, cell-type, or time-specific control. Intersectional logic using two drivers narrows expression to defined subpopulations, and lineage or activity reporters can record recombination history, cell state, and circuit function in vivo [4].</p><p>Safe-harbor or landing-pad workflows at Rosa26 or H11 provide single-copy cassette exchange with fewer position effects. This accelerates iteration of reporters, effectors, and therapeutic payloads. Multifaceted allele designs can combine knock-in cassettes with floxed elements or Lox-Stop-Lox gates to convert reporters into knockouts upon recombination. Somatic and mosaic modeling further expands scope. AAV or LNP delivery introduces editors postnatally for organ-specific perturbations and parallel testing of multiple variants within a single animal [5].</p><p>Conclusions</h3><p>For scientists developing disease models, drug testing platforms, or fundamental genetic interrogation tools, knock-in mice offer unmatched precision, recapitulating native gene function and mutation effects with fidelity. Transgenic mice, while sometimes less precise, provide speed and versatility crucial for broad phenotype screening or studying gene overexpression. Both remain indispensable pillars in the genetics research toolkit, but a careful match between model type and research objective will yield the most robust, translationally relevant discoveries.</p>`,
    publishedAt: "2025-01-01",
  },
  {
    id: "leveraging-mouse-models-for-point-mutation-diseases-r-d-landscape",
    slug: "leveraging-mouse-models-for-point-mutation-diseases-r-d-landscape",
    title: `Leveraging Mouse Models for Point Mutation Diseases: R&D Landscape`,
    subtitle: `Leveraging Mouse Models for Point Mutation Diseases:`,
    description: `How precision mouse genetics is de-risking mutation-targeted therapies from discovery to approval  Point mutation diseases have moved from niche academic focus to the core of high-value pipelines in...`,
    category: "Research",
    relatedPage: "/point-mutation-mice",
    body: `<h2>Point mutation diseases have moved from niche academic focus to the core of high-value pipelines in neurology, rare disease, and genetic oncology. The combination of human genomics and precise mouse engineering means that single-nucleotide variants can be modeled in vivo with exact fidelity, often within a single planning cycle. For biotech, these models are no longer basic research tools. They are strategic assets that determine how quickly a program reaches mechanism-based proof of concept, whether it qualifies for accelerated or breakthrough regulatory pathways, and how convincingly it can support premium pricing in tightly defined patient populations. From antisense therapies in SOD1 ALS to gene replacement in RPE65 blindness and peptide therapies in achondroplasia, mouse models that replicate human point mutations have repeatedly converted genetic insight into approved products. The question for R&amp;D and BD leaders is how to systematize this advantage and use mouse-based precision models to sharpen investment decisions across their entire portfolio.</p><h4>1. Point Mutation Diseases: Current Landscape</strong></h4><p>strategic infrastructure</strong>. They bridge human genetics and drug development by enabling target validation, mechanism-of-action work, and de-risking of first-in-class programs in a whole organism.</p><p><li>CRISPR/Cas9 and related editing tools have made it routine to knock in human SNVs into mice on tight timelines and at reasonable cost.</li><li>The question is no longer whether to use mouse models, but <strong><strong><strong>Across therapeutic areas, mouse models carrying human-relevant point mutations are being used to:</p><ul>Confirm that a given SNV is pathogenic rather than incidental.</li><li>Test whether modulating a specific pathway can reverse or halt disease.</li><li>The examples below illustrate a spectrum from relatively common to ultra-rare monogenic conditions where mouse models have provided decisive translational value.</p><h5>2.2 Select Point Mutation Disease Models</strong></h5><figurew-richtext-figure-type-image w-richtext-align-fullwidth" style="max-width:1024px" data-rt-type="image" data-rt-align="fullwidth" data-rt-max-width="1024px"><divhttps://cdn.prod.website-files.com/665dc660af52559c0ed6ec8b/6935d9bb20f2b57203d5a49d_Screenshot%202025-12-07%20at%202.45.20%E2%80%AFPM.png" loading="lazy" alt="__wf_reserved_inherit" width="auto" height="auto"><strong>a defined mutation, a robust mouse phenotype that mirrors human disease, and a clear link to clinical decision-making</strong> (e.g. dose levels, endpoints, or biomarker choice).</figcaption></figure><h4>3. Strategic Value Proposition: Why Mice Are the Pre-eminent System</strong></h4><p><strong>Mice share the vast majority of protein-coding genes with humans, and many disease pathways are highly conserved. This allows a human SNV to be “transplanted” into a mouse genome and generate:</p><ul>Organ-level pathology (e.g. lung, liver, CNS) rather than single-cell readouts.</li><li>Longitudinal natural history data (onset, progression, survival) in a controlled environment.</li></ul><p>which organs to monitor, which biomarkers to prioritize, and where off-target risks may emerge</strong> before first-in-human studies.</p><h5>3.2 Genetic tractability and CRISPR precision</strong></h5><p>CRISPR/Cas9 and advanced base editors have fundamentally changed the economics of mouse modeling. A human SNV can be knocked into the mouse germline in one or two generations, with:</p><ul>Single-nucleotide precision at the disease-relevant codon.</li><li>Ability to generate multiple allelic variants (e.g. mild and severe mutations) on the same background.</li></ul><p>allele-level modeling</strong>. That is essential when clinical programs target specific mutations (e.g. exon-skipping, ASOs, base editing).</p><h4>3.3 Scalability and cost-effectiveness</strong></h4><p>Mice breed quickly, produce litters large enough for powered preclinical studies, and are well supported by existing vivarium infrastructure. Compared to larger species, they allow:</p><ul>Rapid generation of N≥20–30 per arm for survival, functional, or histopathology endpoints.</li><li>Integration of pharmacology, biomarker, and safety work within a single species and facility.</li></ul><p>higher data yield per dollar and per month</strong> than almost any alternative model.</p><h5>3.4 Regulatory familiarity</strong></h5><p><li>They help justify selection of primary endpoints (e.g. visual function, growth velocity, neurofilament light) that later become key to regulatory approval in small, genotype-defined populations.</li></ul><p>mice sit at the intersection of genetic precision, biological realism, and regulatory familiarity</strong>, which is exactly where high-value point mutation programs need to operate.</p><h4>4. Breakthrough Therapies Enabled by Mouse Models of Point Mutations</strong></h4><p><strong>A fraction of ALS cases are caused by pathogenic point mutations in <em>SOD1</em> mRNA and reduces SOD1 protein levels.</p><p>SOD1</em> mRNA and protein, reversed early loss of compound muscle action potential amplitude, and extended survival by approximately 40–50 days compared with controls, clearly demonstrating disease modification in vivo [2].&nbsp;&nbsp;</p><p>accelerated approval</strong> for Qalsody for SOD1-ALS, based on reduction in plasma neurofilament light as a surrogate marker reasonably likely to predict clinical benefit [3].&nbsp; This is the first therapy targeting a defined genetic cause of ALS, and it would not have progressed without convincing data from point-mutation mouse models.</p><h5>4.2 Luxturna for RPE65 Retinal Dystrophy</strong></h5><p>RPE65</em> mutations cause a severe inherited retinal dystrophy with early childhood blindness. Luxturna (voretigene neparvovec-rzyl) is an AAV2-based gene therapy delivering a functional human <em>Rpe65-deficient rd12 mice, which lack 11-cis-retinal and have severely reduced ERG responses, were a key proof-of-concept system. Subretinal delivery of AAV-RPE65 in these mice restored RPE65 expression over large retinal areas, normalized rhodopsin levels, improved ERG signals, and restored vision-dependent behavior [4].&nbsp; Similar results in RPE65-deficient dogs provided large-animal validation.</p><p>RPE65</em> mutation-associated retinal dystrophy [5].&nbsp; The regulatory package was explicitly built on robust mouse and dog model evidence.</p><h5>4.3 Vosoritide (Voxzogo) for Achondroplasia</strong></h5><p>FGFR3</em> point mutation (c.1138G&gt;A, p.Gly380Arg) that results in a constitutively active receptor and impaired endochondral ossification. Vosoritide (Voxzogo) is a stabilized C-type natriuretic peptide (CNP) analog that activates NPR-B signaling to counteract FGFR3 overactivity.</p><p>Building on this, vosoritide was evaluated in children with achondroplasia. A multinational study showed that once-daily subcutaneous vosoritide produced a sustained increase in annualized growth velocity over multiple years, with a generally mild safety profile [7].&nbsp; The FDA has approved Voxzogo to increase linear growth in children with achondroplasia and open growth plates, making it the first disease-modifying therapy for this FGFR3 point mutation.</p><h4>5. Strategic Implications for Biotech</strong></h4><p><li>Invest early in mutation-exact mouse models.</strong> For any program targeting a well-defined SNV (or small panel of SNVs), a precise knock-in mouse model is no longer optional. It is a key asset for target validation, mechanism, and regulatory positioning.</li><li>Design models with the clinical endpoint in mind.</strong> The most valuable models are those where the mouse phenotype maps cleanly onto a clinically meaningful endpoint (e.g. growth velocity, visual navigation, survival or functional scores) that can support breakthrough or accelerated approval strategies.</li><li>Use models to sharpen patient selection and biomarker strategy.</strong> Mouse data can inform which patients (genotypes, disease stages) are most likely to benefit, and which biomarkers will convincingly demonstrate target engagement and disease modification.</li><li>Choose CRO partners that can execute end-to-end.</strong> For complex point-mutation work, the value comes from an integrated platform: model generation, phenotype characterization, PK/PD, efficacy, and regulatory-grade toxicology under one roof.</li></ol><p>mouse models for point-mutation diseases are not a tactical afterthought but a strategic lever</strong>. They directly influence probability of technical and regulatory success, time to proof-of-concept, and ultimately asset value.</p>`,
    publishedAt: "2025-01-01",
  },
  {
    id: "model-vs-model-humanized-mice-compared-to-organoids-chips-and-ai",
    slug: "model-vs-model-humanized-mice-compared-to-organoids-chips-and-ai",
    title: `Model vs. Model: Humanized Mice Compared to Organoids, Chips, and AI`,
    subtitle: `Harnessing Humanized Mouse Models Part 4`,
    description: `Model vs. Model: How Humanized Mice Compare to Organoids, Chips, and AI  Preclinical Disease Models That Deliver Better Predictive Power   In part 3 we explored how multi-cytokine and dual-organ...`,
    category: "Immunology",
    relatedPage: "/humanized-mouse-models",
    body: `<h3>Model vs. Model: How Humanized Mice Compare to Organoids, Chips, and AI</strong></h3><h4>Preclinical Disease Models That Deliver Better Predictive Power</strong>‍</h4><p>In part 3 we explored how multi-cytokine and dual-organ humanized mouse platforms, such as MISTRG and NSG-SGM3, are advancing disease modeling by enabling human-like hematopoiesis, immune function, and organ-level integration for more physiologically relevant studies of cancer, infection, and inflammation. In <strong>‍</p><h4>Organoids and Organoid–Mouse Hybrids</strong></h4><p>Organoid cultures offer a high-throughput, genetically tractable platform that recapitulates many aspects of human organ architecture. Complex genetic modifications can be achieved in human organoids within weeks, compared to the many months often required to breed transgenic mice. This rapid turnaround makes organoids invaluable for initial mechanistic studies and large-scale drug screens where multiple genetic or pharmacological perturbations need evaluation. Notably, organoids derived from human tissues capture unique cell types and functions that are absent in murine models [1,2]. For example, human intestinal organoids contain motilin-producing enteroendocrine cells and BEST4/OTOP2-expressing absorptive cells that do not exist in the mouse gut, underscoring species-specific physiology that only human-based models can reveal [2]. The ability to establish organoids from patient biopsies also enables personalized disease models, allowing direct study of patient-specific mutations and therapeutic responses in vitro [1]. These strengths position organoids as powerful complements to in vivo studies, filling gaps in human relevance and experimental throughput that traditional mouse models cannot easily address [1].</p><p>Despite their advantages, organoids have fundamental limitations in recapitulating the full complexity of living organs. By nature, organoids lack the vascular perfusion, immune cell repertoire, neural innervation, and mechanical forces present in vivo. This means processes that depend on multicellular interactions across tissues – immune responses, inflammation, endocrinology, or drug pharmacokinetics – are difficult or impossible to model fully in stand-alone organoids. For instance, organoid cultures cannot yet mimic an intact circulatory system or the recruitment of immune cells to a site of infection or tumor. These gaps constrain the utility of organoids for studying systemic diseases or interventions. Recent advances are beginning to bridge these gaps: co-culture systems that add specific stromal or immune components, and <strong>prior</em> to transplantation, researchers can interrogate human gene functions within a living organism,&nbsp; something not feasible with standard mouse models alone.</p><p>Humanized mouse models remain irreplaceable as the <strong>‍</p><h4>Microphysiological Systems (Organs-on-Chips)</strong></h4><p><strong>lung-on-a-chip</strong>, which consists of human alveolar epithelial cells on one side of a porous membrane and capillary endothelial cells on the other, subjected to cyclic stretching to simulate breathing [3]. This system successfully replicated the alveolar–capillary barrier and even showed that physiological breathing motions accentuate nanoparticle absorption and inflammatory responses in the lung. Such biomimetic chips have provided insights into organ function and pathophysiology that are difficult to attain in vivo – for instance, identifying how mechanical forces contribute to lung edema and drug toxicity, or how shear stress influences vascular inflammation. Moreover, because chips are amenable to parallelization, they are useful for high-throughput drug screening under organ-specific conditions. Researchers can test many compounds on identical “organs” arrayed on chips, with automated readouts of barrier integrity, electrophysiology, or other functional metrics. This level of precision and throughput makes MPS platforms valuable for mechanistic studies and initial safety screens in drug development [3].</p><p><strong>multi-organ chip platforms</strong> that connect several organ modules into one circuit, permitting inter-organ crosstalk via a shared perfusion medium [4]. Examples include two-organ partnerships like a gut–liver chip to study oral drug absorption and first-pass metabolism, or more complex “body-on-a-chip” setups linking liver, heart, lung, kidney, and others in physiologically scaled proportions. A recent demonstration interconnected up to ten different human tissue organoids in a closed loop to simulate pharmacokinetics across the whole body [4]. These advances show promise in recapitulating systemic drug distribution and multi-organ toxicities <em>physiologically faithful</strong> (for instance, matching human organ sizes and cell ratios) is an ongoing hurdle. Consequently, even the most advanced MPS cannot yet duplicate an immune system’s complexity or a fully orchestrated pathological response (such as fever or fibrosis involving multiple organs). Regulatory agencies acknowledge these limitations – the U.S. FDA recently noted that while organ-on-chip and other new approach methodologies are promising, they are “not ready to fully replace animal testing” without further validation [5].</p><p>Humanized mice complement MPS by providing the <strong>sequential strategy</strong> is often most powerful: one can use organ-on-chips to identify organ-specific mechanisms or screen compounds under defined conditions, then employ humanized mice to test the most promising findings in an environment that includes all the systemic variables (immune system, neuroendocrine axes, etc.). This way, the strengths of MPS (precision and throughput) are combined with the strengths of animal models (complex integrative physiology), leading to more robust and translatable results.</p><p><strong>‍</p><p>Target Prediction and Virtual Trials:</strong> The rise of in silico modeling and artificial intelligence has added a new dimension to biomedical research. AI-driven computational models can analyze vast datasets – spanning genomics, chemical libraries, clinical records, and more – to generate hypotheses or predictions at a speed and scale no experimental system can match. In drug discovery, machine learning algorithms are now routinely used to predict drug–target interactions and optimize lead compounds. For instance, AI models can screen millions of chemical structures against a target protein in silico to prioritize those most likely to bind strongly, focusing experimental testing on only the top candidates. This greatly accelerates the early-phase discovery process. AI can also suggest modifications to improve a drug’s pharmacokinetics or reduce toxicity by learning from large datasets of previous compounds. Beyond discovery, <strong>‍</p><p>Gaps in Biological Complexity:</strong> For all their promise, purely computational models have important limitations. <strong>experimental validation remains essential</strong>. Humanized mice serve as an important proving ground for AI-generated hypotheses in a setting that approximates human physiology. For example, if a machine learning model flags a new oncology drug as effective against a human tumor based on <em>omic data</em>, one can test this by engrafting the patient’s tumor into an immune-humanized mouse to see if the predicted response occurs <em>discrepancies between in silico predictions and in vivo outcomes</strong> provide invaluable feedback to refine the models. This synergy between AI and animal models is increasingly recognized as the optimal path forward: use AI to narrow the search space and design candidates, then use human-relevant experimental models to verify and further explore those candidates. Indeed, regulatory agencies are crafting frameworks to integrate AI into the drug development pipeline alongside traditional testing. The FDA recently issued guidance on using AI for drug development and is funding initiatives to qualify in silico models as part of regulatory submissions [5]. Nonetheless, the consensus is that while AI can drastically streamline research, it <strong>‍</p><h4>Why Integration Matters</strong></h4><p>In the landscape of modern biomedical research, advanced models like organoids, microphysiological systems, and in silico simulations should not be viewed as competitors to humanized mice, but rather as complementary tools that operate at different scales [6]. Each model system has distinct strengths and blind spots. By strategically integrating these approaches, scientists can leverage the best of each while mitigating their individual limitations. For example, a logical workflow might proceed as follows:&nbsp;</p><p><li>Apply organoid or organ-on-chip models to test the top candidates or hypotheses in a controlled human-cell context, rapidly obtaining data on efficacy, mechanism, and organ-specific toxicity.&nbsp;</li><li>‍</p><p>in vitro</em> human models act as filters before any compound ever enters animal testing. This not only saves time and resources but also aligns with ethical efforts to minimize animal use.</p><p>Moreover, <strong>‍</p><p>New Approach Methodologies (NAMs)</strong> – which include organoids, organ-on-chips, and computational models – to supplement and in some cases replace traditional animal studies. In 2022, the U.S. Congress passed the FDA Modernization Act 2.0, which removed the historical mandate for animal testing in drug approval if valid alternative methods are available. This policy shift, along with the FDA’s April 2025 roadmap, envisions that animal tests will become the exception rather than the norm in preclinical safety studies within the next few years [5]. However, regulators are clear that alternative models must demonstrate their reliability and relevance before displacing animal models entirely. In practice, this means an integrated approach: using organoids and chips for what they do best (human-specific and mechanistic insights) and using humanized mice as the <strong>in vitro</em> human models, and <em>‍</p><h4>Conclusion</strong></h4><p>Alternative model systems – organoids, organ-on-chip microphysiological systems, and in silico simulations – have each expanded what is possible in biomedical research, offering insights at speeds and resolutions that traditional animal models alone could never achieve. Yet, rather than displacing animal models, these technologies are becoming collaborators with them. Humanized mice remain a cornerstone for modeling the integrated physiology of human diseases, especially when immune, endocrine, and multi-organ interactions are involved. The consensus emerging in the field is that <strong>synthesis of evidence</strong> across models. Organoids and chips can provide early-stage, human-specific data, and AI can guide decision-making, but humanized mice supply the ultimate test of whether those findings hold in a living, complex organism. As the FDA’s recent actions highlight, the future of preclinical research will increasingly rely on a toolkit of complementary models. Rather than a competition of “model vs. model,” the paradigm is shifting to cooperation: <em>in vitro</em> models refine and test them under defined conditions, and <em id=">in vivo</em> humanized models confirm and expand the results in a system as close to a human patient as possible. Embracing this integrated approach will improve translational predictability — getting therapies from bench to bedside more efficiently — while also reducing redundant animal usage. In summary, humanized mice, organoids, chips, and AI should be seen as synergistic parts of a single research ecosystem. When used in concert, they can accelerate discovery and development in ways none of them could accomplish alone, ultimately benefitting patients by delivering new treatments that have been rigorously vetted from every angle.</p>`,
    publishedAt: "2025-01-01",
  },
  {
    id: "modeling-complexity-multi-cytokine-and-multi-organ-humanization",
    slug: "modeling-complexity-multi-cytokine-and-multi-organ-humanization",
    title: `Modeling Complexity: Multi-Cytokine and Multi-Organ Humanization`,
    subtitle: `Harnessing Humanized Mouse Models - Part 3`,
    description: `Modeling Complexity: Multi-Cytokine and Multi-Organ Humanization  Preclinical Disease Models That Deliver Better Predictive Power  In part 2 of this series on humanized mouse models, we examined how...`,
    category: "Research",
    relatedPage: "/custom-mouse-models",
    body: `<h3>Modeling Complexity: Multi-Cytokine and Multi-Organ Humanization</strong></h3><h4>‍<br>Preclinical Disease Models That Deliver Better Predictive Power</strong></h4><h4>MISTRG Mice</strong></h4><p>MISTRG</strong> platform (Macrophage colony-stimulating factor, Interleukin-3, Stem cell factor, Thrombopoietin, Rag2-/-, IL2Rγ-/-) introduced a breakthrough in multi-cytokine support for human hematopoietic and immune development. By replacing murine loci with human M-CSF, IL-3/GM-CSF, SCF, and TPO, these mice provide physiological cytokine expression that enables robust engraftment and differentiation of human HSCs into macrophages, dendritic cells, granulocytes, and NK cells <a href="https://docs.google.com/document/d/1HWGcCM_OwRo1v50c02CZ7fWaN_roZUhUY8ZvhTZwSjM/edit?tab=t.0#heading=h.j3hsan1rd9at">‍</p><h4>Cytokine Knock-ins and Hematopoiesis</strong></h4><phttps://docs.google.com/document/d/1HWGcCM_OwRo1v50c02CZ7fWaN_roZUhUY8ZvhTZwSjM/edit?tab=t.0#heading=h.j3hsan1rd9at">‍</p><h4>Applications in Myelodysplastic Syndrome and Cancer</strong></h4><p>myelodysplastic syndromes (MDS)</strong>. Song et al. showed that MISTRG faithfully reproduced patient-derived MDS with preservation of dysplastic morphology, lineage diversity (including erythroid and megakaryocytic), and clonal architecture <a href="https://docs.google.com/document/d/1HWGcCM_OwRo1v50c02CZ7fWaN_roZUhUY8ZvhTZwSjM/edit?tab=t.0#heading=h.j3hsan1rd9at"https://docs.google.com/document/d/1HWGcCM_OwRo1v50c02CZ7fWaN_roZUhUY8ZvhTZwSjM/edit?tab=t.0#heading=h.j3hsan1rd9at">The robust immune reconstitution in MISTRG also benefits immuno-oncology studies, where tumor–immune cell interactions can be faithfully modeled <a href="https://docs.google.com/document/d/1HWGcCM_OwRo1v50c02CZ7fWaN_roZUhUY8ZvhTZwSjM/edit?tab=t.0#heading=h.j3hsan1rd9at">‍</p><h4>NSG-SGM3 and Specialized Cytokine Models</strong></h4><p>NSG-SGM3</strong> strain carries human SCF, GM-CSF, and IL-3, which together create a highly supportive niche for hematopoiesis and acute myeloid leukemia (AML) xenografts. This platform enables engraftment of patient-derived AML samples otherwise non-engraftable in conventional NSG, thereby expanding translational leukemia research <a href="https://docs.google.com/document/d/1HWGcCM_OwRo1v50c02CZ7fWaN_roZUhUY8ZvhTZwSjM/edit?tab=t.0#heading=h.j3hsan1rd9at"https://docs.google.com/document/d/1HWGcCM_OwRo1v50c02CZ7fWaN_roZUhUY8ZvhTZwSjM/edit?tab=t.0#heading=h.j3hsan1rd9at">‍</p><h4>IL-3/GM-CSF Knock-ins for Pulmonary Immunity</strong></h4><phttps://docs.google.com/document/d/1HWGcCM_OwRo1v50c02CZ7fWaN_roZUhUY8ZvhTZwSjM/edit?tab=t.0#heading=h.j3hsan1rd9at">‍</p><h4>Dual Humanization Platforms</strong></h4><p><li>Immune + Liver (FAH KO):</strong> Allows concurrent human hepatocyte and immune system engraftment, supporting studies of hepatitis virus infections and drug-induced liver injury.</li><li>Immune + Lung (BLT-L):</strong> Supports parallel human immune and lung tissue reconstitution, enabling research into chronic pulmonary inflammation and viral pathogenesis.</li></ul><p>interconnected human physiology</strong> <a href="https://docs.google.com/document/d/1HWGcCM_OwRo1v50c02CZ7fWaN_roZUhUY8ZvhTZwSjM/edit?tab=t.0#heading=h.j3hsan1rd9at">‍</p><h4>Conclusion</strong></h4><p>multi-cytokine, dual-organ humanization</strong> reflects a paradigm shift toward in vivo systems capable of recapitulating <stronghttps://docs.google.com/document/d/1HWGcCM_OwRo1v50c02CZ7fWaN_roZUhUY8ZvhTZwSjM/edit?tab=t.0#heading=h.j3hsan1rd9at">‍</p>`,
    publishedAt: "2025-01-01",
  },
  {
    id: "the-impact-of-knockout-and-knock-in-mouse-models-on-biomedical-research",
    slug: "the-impact-of-knockout-and-knock-in-mouse-models-on-biomedical-research",
    title: `The Impact of Knockout and Knock-in Mouse Models on Biomedical Research`,
    subtitle: `The Impact of Knockout and Knock-in Mouse Models on Biomedical Research`,
    description: `Knockout and knock-in mouse models have fundamentally transformed biomedical research, enabling scientists to dissect gene function and the genetic basis of many diseases. Through precise genetic...`,
    category: "Technical Guide",
    relatedPage: "/knockin-mouse-models",
    body: `<h3>‍</p><pknocked out." The primary goal is to observe what happens when a particular gene loses function, revealing its physiological role. This strategy has yielded crucial insights into diseases such as cancer (p53 KO mice), metabolic disorders (insulin receptor knockout mice), and neurodegenerative diseases (APP, presenilin knockout mice for Alzheimer's) <a href="https://docs.google.com/document/d/1GGADjuZXBWeIvh3CN8qB9Ry6jsAtJj8D-ubYEm8S0D8/edit?tab=t.0#heading=h.sv01nwtyv3q5">[1</sup></a><sup>The historic development of knockout&nbsp; and knock-in&nbsp; mouse models is a landmark in genetic research, recognized as a key advance in understanding gene function and disease. The creation of knockout mice became possible after the isolation and cultivation of embryonic stem (ES) cells from mice in 1981, an achievement by Martin J. Evans and others. This advance enabled researchers to manipulate the mouse genome in ES cells and later introduce these cells into developing embryos, resulting in animals with targeted gene mutations. Using these techniques, Mario Capecchi, Oliver Smithies, and Martin Evans produced the first knockout mouse in 1989. For this transformative work, all three scientists received the Nobel Prize in Physiology or Medicine in 2007 <a href="https://docs.google.com/document/d/1GGADjuZXBWeIvh3CN8qB9Ry6jsAtJj8D-ubYEm8S0D8/edit?tab=t.0#heading=h.sv01nwtyv3q5">[2]</sup></a>. The fundamental technique used—homologous recombination in ES cells—allowed scientists to hijack the cellular DNA repair/recombination machinery to exquisitely alter, and therefore inactivate (hence "knock out") specific genes. This not only let them observe the resulting physiological effects, but also enabled systematic study of gene function, which was previously impossible in mammals.</p><phttps://docs.google.com/document/d/1GGADjuZXBWeIvh3CN8qB9Ry6jsAtJj8D-ubYEm8S0D8/edit?tab=t.0#heading=h.sv01nwtyv3q5">[3]</sup></a>. This allows for modeling specific human genetic variants and studying their effects in a controlled environment</p><p>Key Applications and Scientific Impact</h3><p>Disease Modeling</h5><phttps://docs.google.com/document/d/1GGADjuZXBWeIvh3CN8qB9Ry6jsAtJj8D-ubYEm8S0D8/edit?tab=t.0#heading=h.sv01nwtyv3q5">[</sup></a><sup>Knock-in models expanded research capacity by introducing mutations identical to those in patients. For instance, knock-in mice expressing mutant <emhttps://docs.google.com/document/d/1GGADjuZXBWeIvh3CN8qB9Ry6jsAtJj8D-ubYEm8S0D8/edit?tab=t.0#heading=h.sv01nwtyv3q5">[3][5][6]</sup></a>.</p><p>Drug Development and Preclinical Testing</h5><p>Both knockout and knock-in mice serve as preclinical platforms for drug testing and safety assessment, reducing risk before human trials. Humanized knock-in models carrying human gene sequences enhance predictive power for drug metabolism and efficacy<a href="https://docs.google.com/document/d/1GGADjuZXBWeIvh3CN8qB9Ry6jsAtJj8D-ubYEm8S0D8/edit?tab=t.0#heading=h.sv01nwtyv3q5">[7]</sup></a>.</p><p>Conditional Knockout/Knock-in</h5><p>Traditional knockout models often suffer from embryonic lethality when targeting essential genes, limiting adult studies. This has been overcome by conditional knockout &amp; knock-in strategies—such as the Cre/loxP and FLP systems—allowing gene modification in specific tissues or developmental stages <a href="https://docs.google.com/document/d/1GGADjuZXBWeIvh3CN8qB9Ry6jsAtJj8D-ubYEm8S0D8/edit?tab=t.0#heading=h.sv01nwtyv3q5">[8]</sup></a>. The development of "knock-in first" approaches has further enhanced model utility. These systems incorporate reporter cassettes and conditional elements, allowing researchers to create constitutive knockouts, conditional knockouts, or hypomorphic alleles from a single targeting event. This versatility has proven particularly valuable in complex disease modeling where different levels of gene expression may be required <a href="https://docs.google.com/document/d/1GGADjuZXBWeIvh3CN8qB9Ry6jsAtJj8D-ubYEm8S0D8/edit?tab=t.0#heading=h.sv01nwtyv3q5">[9]</sup></a>.</p><p>Technological Evolution: From ES Cells to CRISPR</h5><p>Knockout/Knock-in mouse generation began with homologous recombination in embryonic stem (ES) cells. Recently, CRISPR/Cas effector technologies accelerated model creation, cutting timelines and costs due to the low targeting efficiency of homologous recombination mechanisms in mammalian cells that initial Knockout/Knock-in relied on, but fundamental Knockout/Knock-in discoveries remain pivotal . Newer tools like prime and base editing offer finer, more versatile genetic manipulation, though their role is currently supplementary to Knockout/Knock-in research <a href="https://docs.google.com/document/d/1GGADjuZXBWeIvh3CN8qB9Ry6jsAtJj8D-ubYEm8S0D8/edit?tab=t.0#heading=h.sv01nwtyv3q5">[10], [11]</sup></a>.</p><p>Conclusion</h5><p>Knockout and Knock-in mouse models are central to genetic and disease research, enabling precise studies that have driven countless medical breakthroughs. They remain essential tools, bridging molecular discovery and clinical therapies as genome editing evolves.</p><p id=">‍</p>`,
    publishedAt: "2025-01-01",
  },
  {
    id: "top-5-lab-mouse-colony-management-software-options-for-2025",
    slug: "top-5-lab-mouse-colony-management-software-options-for-2025",
    title: `Top 5 Lab Mouse Colony Management Software Options For 2025`,
    subtitle: `TOP 5 LAB MOUSE COLONY MANAGEMENT`,
    description: `Managing a mouse colony effectively is a critical but often underestimated aspect of laboratory research. Whether you’re creating a new mouse model tailored to your study or purchasing an existing...`,
    category: "Resources",
    relatedPage: "/breeding-scheme-architect",
    body: `<p>If your lab relies on spreadsheets or basic tools like Microsoft Access, you may already be familiar with the frustrations of static data tracking. These tools can quickly become cumbersome, leading to disorganization and potentially costly errors in your research data. Without the right tools, staying on top of breeding, genotyping, and cage organization as your colony expands can feel overwhelming.</p><p>This is where investing in dedicated colony management software can make all the difference. With the right solution, your lab can:</p><p>Streamline animal tracking</strong>: Consolidate all data into an intuitive, centralized platform.</p><p>Improve organization</strong>: Easily monitor cage details, breeding schedules, and lineage tracking.</p><p>Ensure compliance</strong>: Stay ahead of animal welfare laws and regulatory requirements.</p><p>Save time and resources</strong>: Reduce administrative overhead, allowing researchers to focus on science.</p><p>As your lab’s needs evolve, colony management software provides the scalability and flexibility required to maintain order, accuracy, and compliance. Adopting these tools enhances operational efficiency and frees up critical resources to advance research goals.</p><p>As of January 2025, mouse colony management systems have evolved to offer comprehensive, web-based solutions that streamline the complexities of managing laboratory mouse colonies. These platforms enhance efficiency, accuracy, and compliance in research settings.</p><p>Here Are The Top 5 Lab Mouse Colony Management Software Options We Found, As Recommended By <a href="https://www.researchgate.net/post/Can_anyone_recommend_a_mouse_colony_management_software_system"https://www.researchgate.net/post/Is_there_a_software_free_or_cheap_to_manage_animal_breeding">‍</p><p>1) </strong><a href="https://www.softmouse.net/">SoftMouse.NET</strong></a><strong>SoftMouse.NET is still the most widely adopted colony management software among academic institutions. It is known for its user-friendly interface and cost-effective solutions. It offers a "FOREVER FREE" plan tailored for individual users and smaller labs, enabling efficient tracking of relational data between mice and supplies without the need for advanced features.</p><p>For laboratories requiring more comprehensive functionalities, SoftMouse.NET provides a "PREMIUM" option, which includes:</p><ul><strong><strong><strong><strong><strong><strong>Both plans include free, unlimited technical support, ensuring users receive assistance as needed.</p><p>Users have reported significant improvements in efficiency and usability over the years, as commented on Researchgate. One researcher noted a 75% increase in speed compared to previous methods, while another praised the intuitive interface that facilitated quick adaptation among colleagues.</p><p><stronghttps://bioinforx.com/lims2/product_mlims.php">mLIMS</strong></a><strong>mLIMS has offered efficient mouse breeding colony management solutions for almost two decades. This user-friendly, web-based software stores real-time data in the cloud and is optimized for mobile devices, enabling researchers to manage their colonies anywhere. By consolidating multiple processes into a single workflow, mLIMS aims to streamline laboratory operations, ultimately saving time and resources.&nbsp;&nbsp;</p><p>	•	<strong>	•	<strong>	•	<strong>	•	<strong>	•	<strong>All versions include animal and cage management tools, breeding, protocol tracking, and features such as email notifications and built-in reporting.&nbsp;&nbsp;</p><p>3) </strong><a href="https://www.scionics.com/pyrat.html">PyRAT Animal Facility Software</strong></a><strong>PyRAT, a web-based mouse colony management system, aims to help labs simplify their processes and save money. It features billing, invoicing, visualizing data, and complying with legislation easily. Other features support mouse breeding charts, mouse genotyping services, ordering services and supplies, and more. This animal facility software is available to users globally and offers English, French, German, Italian, Portuguese, and Spanish language support.</p><p>4) </strong><a href="https://www.rockstepsolutions.com/">Climb™</strong></a><strong>Climb™ 2.0’s software was developed to help labs in biotech, pharma, CRO, and academic spaces manage their overall studies. Colony management and veterinary care are just some of the main features, alongside biological sample management, analysis, and protocol management. Others include animal welfare compliance, data delivery, and remote study planning and scheduling. Climb™ has also partnered with Scientist.com to allow users to order scientific materials remotely.</p><p>To find out if Climb-A™, or Climb™’s full suite of features, would be a good fit for your lab, you can schedule a demo with their experts.</p><p><stronghttp://www.mousej.org">Mouse J</strong></a><strong>Mouse J was developed by an academic scientist for the benefit of the scientific community and thus is distributed fully for free. MouseJ is a lightweight and interactive mouse colony management software designed specifically for research laboratories. It emphasizes simplicity and usability, allowing users to view all essential information on a single screen. Features include a refined main interface with icons and images, a calendar function for essential dates like weaning and timed pregnancies, and the ability to import and export data to Excel. These functionalities have contributed to its growing popularity among small research labs seeking an efficient, straightforward solution for managing mouse colonies.</p><pen">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Mouse Colony Management Software Comparison</title>
  <link href="https://fonts.googleapis.com/css2?family=Lato:wght@300;400;700&family=Poppins:wght@400;600;700;900&display=swap" rel="stylesheet">
  <style>
    body {
      margin: 0;
      padding: 0;
      background: #eef3f6;
      font-family: 'Lato', sans-serif;
    }

    .mouse-colony-cards {
      max-width: 1400px;
      margin: 32px auto;
      padding: 16px;
      background: rgba(255,255,255,0.95);
      border-radius: 20px;
      box-shadow: 0 20px 40px rgba(0,0,0,0.08);
      backdrop-filter: blur(10px);
    }

    .mc-header {
      background: linear-gradient(135deg, #4facfe 0%, #00f2fe 100%);
      color: #fff;
      padding: 32px 20px 18px 20px;
      border-radius: 16px 16px 0 0;
      text-align: center;
      margin-bottom: 24px;
    }
    .mc-header h1 {
      font-family: 'Poppins', sans-serif;
      font-weight: 900;
      font-size: 2.2em;
      margin-bottom: 10px;
      letter-spacing: 0.5px;
    }
    .mc-header p {
      font-size: 1.1em;
      opacity: 0.93;
    }

    .mc-grid {
      display: grid;
      grid-template-columns: repeat(3, 1fr);
      gap: 28px;
    }

    .mc-card {
      background: #fff;
      border-radius: 16px;
      box-shadow: 0 6px 24px rgba(0,0,0,0.07);
      padding: 24px 20px 20px 20px;
      display: flex;
      flex-direction: column;
      justify-content: flex-start;
      transition: box-shadow 0.2s;
      position: relative;
    }
    .mc-card:hover {
      box-shadow: 0 10px 32px rgba(79, 172, 254, 0.10), 0 2px 8px rgba(0,0,0,0.06);
      z-index: 1;
    }

    .mc-software {
      font-family: 'Poppins', sans-serif;
      font-size: 1.13em;
      font-weight: 700;
      color: #2c3e50;
      margin-bottom: 7px;
    }
    .mc-software a {
      color: #4facfe;
      text-decoration: none;
      border-bottom: 2px solid transparent;
      transition: border-color 0.25s;
    }
    .mc-software a:hover {
      border-bottom: 2px solid #4facfe;
    }
    .mc-features {
      margin: 0 0 7px 0;
      padding: 0 0 0 0;
    }
    .mc-features ul {
      margin: 0;
      padding-left: 18px;
      font-size: 0.97em;
    }
    .mc-features li {
      margin-bottom: 2px;
      list-style: none;
      position: relative;
      padding-left: 16px;
    }
    .mc-features li:before {
      content: "✓";
      position: absolute;
      left: 0;
      color: #27ae60;
      font-weight: bold;
    }

    .mc-row {
      display: flex;
      flex-wrap: wrap;
      gap: 12px 0;
      margin-bottom: 3px;
    }
    .mc-label {
      min-width: 96px;
      font-family: 'Poppins', sans-serif;
      font-size: 12px;
      color: #a2b2be;
      text-transform: uppercase;
      font-weight: 600;
      margin-right: 6px;
      letter-spacing: 0.2px;
      flex: 0 0 105px;
    }
    .mc-value {
      font-size: 1em;
      font-weight: 500;
      color: #34495e;
      flex: 1 1 120px;
    }

    .mc-cost-free {
      background: linear-gradient(135deg, #00b09b, #96c93d);
      -webkit-background-clip: text;
      -webkit-text-fill-color: transparent;
      background-clip: text;
      text-fill-color: transparent;
      font-weight: 700;
      display: inline-block;
    }

    .mc-platform-tags {
      display: flex;
      flex-wrap: wrap;
      gap: 6px;
    }
    .mc-platform-tag {
      background: #ecf0f1;
      color: #2c3e50;
      padding: 3px 10px;
      border-radius: 12px;
      font-size: 11px;
      font-weight: 500;
    }

    .mc-user-base {
      display: inline-block;
      text-align: center;
      font-weight: 600;
      padding: 4px 13px;
      border-radius: 20px;
      color: white;
      font-size: 12px;
      text-transform: uppercase;
      letter-spacing: 0.5px;
      margin-bottom: 3px;
    }
    .mc-user-high {
      background: linear-gradient(135deg, #27ae60, #2ecc71);
    }
    .mc-user-medium {
      background: linear-gradient(135deg, #f39c12, #e67e22);
    }
    .mc-user-low {
      background: linear-gradient(135deg, #e74c3c, #c0392b);
    }
    .mc-not-specified {
      color: #95a5a6;
      font-style: italic;
      font-size: 1em;
    }
    .mc-section-divider {
      grid-column: 1 / -1;
      text-align: center;
      font-family: 'Poppins',sans-serif;
      color: #fff;
      background: linear-gradient(90deg, #667eea 0%, #764ba2 100%);
      font-size: 1em;
      font-weight: 700;
      padding: 10px 0 11px 0;
      border-radius: 12px;
      margin: 22px 0 8px 0;
    }
    /* Tablet (2 columns) */
    @media (max-width: 1100px) {
      .mc-grid {
        grid-template-columns: repeat(2, 1fr);
      }
    }
    /* Mobile (1 column) */
    @media (max-width: 700px) {
      .mouse-colony-cards {
        padding: 2px;
        border-radius: 10px;
        margin: 6px;
      }
      .mc-header {
        font-size: 1em;
        padding: 18px 8px 14px 8px;
        border-radius: 12px 12px 0 0;
      }
      .mc-header h1 {
        font-size: 1.1em;
        margin-bottom: 4px;
      }
      .mc-grid {
        grid-template-columns: 1fr;
        gap: 16px;
      }
      .mc-card {
        border-radius: 10px;
        padding: 14px 8px 12px 8px;
      }
    }
  </style>
</head>
<body>
  <div class="mouse-colony-cards">
    <div class="mc-header">
      <h1>Mouse Colony Management Software Comparison</h1>
      <p>Comprehensive overview of leading laboratory mouse colony management solutions for 2025</p>
    </div>
    <div class="mc-grid">
      <!-- Card 1 -->
      <div class="mc-card">
        <div class="mc-software"><a href="http://softmouse.net" target="_blank">SoftMouse.NET</a></div>
        <div class="mc-features">
          <ul>
            <li>Easy-to-use interface</li>
            <li>Breeding schemas</li>
            <li>Family trees</li>
            <li>Email alerts</li>
          </ul>
        </div>
        <div class="mc-row">
          <div class="mc-label">Cost:</div>
          <div class="mc-value">
            <span class="mc-cost-free">Free version available</span><br>
            Premium: ~$600/year for 5 users
          </div>
        </div>
        <div class="mc-row">
          <div class="mc-label">Platforms:</div>
          <div class="mc-value">
            <div class="mc-platform-tags">
              <span class="mc-platform-tag">Web-based</span>
              <span class="mc-platform-tag">Mobile</span>
            </div>
          </div>
        </div>
        <div class="mc-row">
          <div class="mc-label">Last Updated:</div>
          <div class="mc-value">2024</div>
        </div>
        <div class="mc-row">
          <div class="mc-label">First Released:</div>
          <div class="mc-value">2007</div>
        </div>
        <div class="mc-row">
          <div class="mc-label">Estimated Users:</div>
          <div class="mc-value"><span class="mc-user-base mc-user-high">High</span></div>
        </div>
      </div>
      <!-- Card 2 -->
      <div class="mc-card">
        <div class="mc-software"><a href="https://bioinforx.com/web/product_mlims.php?t" target="_blank">mLIMS</a></div>
        <div class="mc-features">
          <ul>
            <li>Cloud-based real-time data storage</li>
            <li>Multiple versions</li>
            <li>Protocol tracking</li>
          </ul>
        </div>
        <div class="mc-row">
          <div class="mc-label">Cost:</div>
          <div class="mc-value">Varies by version<br><em>(Contact for pricing)</em></div>
        </div>
        <div class="mc-row">
          <div class="mc-label">Platforms:</div>
          <div class="mc-value">
            <div class="mc-platform-tags">
              <span class="mc-platform-tag">Web-based</span>
              <span class="mc-platform-tag">Mobile</span>
            </div>
          </div>
        </div>
        <div class="mc-row">
          <div class="mc-label">Last Updated:</div>
          <div class="mc-value">2024</div>
        </div>
        <div class="mc-row">
          <div class="mc-label">First Released:</div>
          <div class="mc-value">2006</div>
        </div>
        <div class="mc-row">
          <div class="mc-label">Estimated Users:</div>
          <div class="mc-value"><span class="mc-user-base mc-user-high">High</span></div>
        </div>
      </div>
      <!-- Card 3 -->
      <div class="mc-card">
        <div class="mc-software"><a href="https://www.scionics.com/pyrat.html" target="_blank">PyRAT</a></div>
        <div class="mc-features">
          <ul>
            <li>Billing and invoicing</li>
            <li>Data visualization</li>
            <li>Multi-language support</li>
          </ul>
        </div>
        <div class="mc-row">
          <div class="mc-label">Cost:</div>
          <div class="mc-value">Contact for pricing</div>
        </div>
        <div class="mc-row">
          <div class="mc-label">Platforms:</div>
          <div class="mc-value">
            <div class="mc-platform-tags">
              <span class="mc-platform-tag">Web-based</span>
            </div>
          </div>
        </div>
        <div class="mc-row">
          <div class="mc-label">Last Updated:</div>
          <div class="mc-value">2024</div>
        </div>
        <div class="mc-row">
          <div class="mc-label">First Released:</div>
          <div class="mc-value mc-not-specified">Not specified</div>
        </div>
        <div class="mc-row">
          <div class="mc-label">Estimated Users:</div>
          <div class="mc-value"><span class="mc-user-base mc-user-medium">Medium</span></div>
        </div>
      </div>
      <!-- Card 4 -->
      <div class="mc-card">
        <div class="mc-software"><a href="https://www.rockstepsolutions.com/study-and-protocol-management/" target="_blank">Climb™</a></div>
        <div class="mc-features">
          <ul>
            <li>Customizable options</li>
            <li>Optimized for R&D labs</li>
          </ul>
        </div>
        <div class="mc-row">
          <div class="mc-label">Cost:</div>
          <div class="mc-value">Contact for pricing</div>
        </div>
        <div class="mc-row">
          <div class="mc-label">Platforms:</div>
          <div class="mc-value mc-not-specified">Not specified</div>
        </div>
        <div class="mc-row">
          <div class="mc-label">Last Updated:</div>
          <div class="mc-value">2024</div>
        </div>
        <div class="mc-row">
          <div class="mc-label">First Released:</div>
          <div class="mc-value mc-not-specified">Not specified</div>
        </div>
        <div class="mc-row">
          <div class="mc-label">Estimated Users:</div>
          <div class="mc-value"><span class="mc-user-base mc-user-medium">Medium</span></div>
        </div>
      </div>
      <!-- Section divider card -->
      <div class="mc-section-divider">Other options with very low or niche users</div>
      <!-- Card 5 -->
      <div class="mc-card">
        <div class="mc-software"><a href="https://github.com/myvivarium/MyVivarium" target="_blank">MyVivarium</a></div>
        <div class="mc-features">
          <ul>
            <li>QR code-enhanced cage cards</li>
            <li>Task assignments and reminders</li>
            <li>IoT-based ambient sensing</li>
          </ul>
        </div>
        <div class="mc-row">
          <div class="mc-label">Cost:</div>
          <div class="mc-value">Contact for pricing</div>
        </div>
        <div class="mc-row">
          <div class="mc-label">Platforms:</div>
          <div class="mc-value">
            <div class="mc-platform-tags">
              <span class="mc-platform-tag">Web-based</span>
              <span class="mc-platform-tag">Mobile</span>
            </div>
          </div>
        </div>
        <div class="mc-row">
          <div class="mc-label">Last Updated:</div>
          <div class="mc-value">2024</div>
        </div>
        <div class="mc-row">
          <div class="mc-label">First Released:</div>
          <div class="mc-value mc-not-specified">Not specified</div>
        </div>
        <div class="mc-row">
          <div class="mc-label">Estimated Users:</div>
          <div class="mc-value"><span class="mc-user-base mc-user-low">Very Low</span></div>
        </div>
      </div>
      <!-- Card 6 -->
      <div class="mc-card">
        <div class="mc-software"><a href="http://www.maus-o-leum.de" target="_blank">Mausoleum</a></div>
        <div class="mc-features">
          <ul>
            <li>Drag-and-drop functionality</li>
            <li>Automatic cage detection for breeding</li>
          </ul>
        </div>
        <div class="mc-row">
          <div class="mc-label">Cost:</div>
          <div class="mc-value">One-time server license fee + additional client licenses</div>
        </div>
        <div class="mc-row">
          <div class="mc-label">Platforms:</div>
          <div class="mc-value">
            <div class="mc-platform-tags">
              <span class="mc-platform-tag">Windows</span>
              <span class="mc-platform-tag">OSX</span>
              <span class="mc-platform-tag">Linux</span>
            </div>
          </div>
        </div>
        <div class="mc-row">
          <div class="mc-label">Last Updated:</div>
          <div class="mc-value">2024</div>
        </div>
        <div class="mc-row">
          <div class="mc-label">First Released:</div>
          <div class="mc-value mc-not-specified">Not specified</div>
        </div>
        <div class="mc-row">
          <div class="mc-label">Estimated Users:</div>
          <div class="mc-value"><span class="mc-user-base mc-user-low">Very Low</span></div>
        </div>
      </div>
      <!-- Card 7 -->
      <div class="mc-card">
        <div class="mc-software"><a href="https://github.com/UCSF-MS-DCC/TopoDB" target="_blank">TopoDB</a></div>
        <div class="mc-features">
          <ul>
            <li>Individual animal tracking</li>
            <li>Genetic and phenotypic data storage</li>
            <li>Preliminary data analysis</li>
          </ul>
        </div>
        <div class="mc-row">
          <div class="mc-label">Cost:</div>
          <div class="mc-value mc-not-specified">Not specified</div>
        </div>
        <div class="mc-row">
          <div class="mc-label">Platforms:</div>
          <div class="mc-value">
            <div class="mc-platform-tags">
              <span class="mc-platform-tag">Web-based</span>
            </div>
          </div>
        </div>
        <div class="mc-row">
          <div class="mc-label">Last Updated:</div>
          <div class="mc-value">2020</div>
        </div>
        <div class="mc-row">
          <div class="mc-label">First Released:</div>
          <div class="mc-value">2020</div>
        </div>
        <div class="mc-row">
          <div class="mc-label">Estimated Users:</div>
          <div class="mc-value"><span class="mc-user-base mc-user-low">Very Low</span></div>
        </div>
      </div>
      <!-- Card 8 -->
      <div class="mc-card">
        <div class="mc-software"><a href="http://www.mousej.org" target="_blank">MouseJ</a></div>
        <div class="mc-features">
          <ul>
            <li>Free and open-source</li>
            <li>Easy data sharing</li>
            <li>Simple colony management</li>
          </ul>
        </div>
        <div class="mc-row">
          <div class="mc-label">Cost:</div>
          <div class="mc-value"><span class="mc-cost-free">Free</span></div>
        </div>
        <div class="mc-row">
          <div class="mc-label">Platforms:</div>
          <div class="mc-value">
            <div class="mc-platform-tags">
              <span class="mc-platform-tag">Windows</span>
            </div>
          </div>
        </div>
        <div class="mc-row">
          <div class="mc-label">Last Updated:</div>
          <div class="mc-value mc-not-specified">Not specified</div>
        </div>
        <div class="mc-row">
          <div class="mc-label">First Released:</div>
          <div class="mc-value">2019</div>
        </div>
        <div class="mc-row">
          <div class="mc-label">Estimated Users:</div>
          <div class="mc-value"><span class="mc-user-base mc-user-low">Very Low</span></div>
        </div>
      </div>
    </div>
  </div>
</body>
</html></div><p>Bonus:</strong> <a href="https://go.genetargeting.com/mouse-breeding-planner-ingenious">Mouse Breeding Planner</strong></a> By Ingenious Targeting Laboratory</p><p>Before trying out any software options discussed here, you can get a headstart on your mouse colony with our exclusive <a href="https://go.genetargeting.com/mouse-breeding-planner-ingenious">Breeding Planner</strong></a>. This free software allows you to create a fully customized breeding plan before your mice arrive at your facility. Our guided software will help you predict the time and cost of your project based on your strain’s breeding performance and your facility’s operating costs. You can also quickly compare different breeding options with the graphical output feature.</p><p>We hope you’ve found this article helpful and that you can choose the ideal lab animal management software for your lab!</p><p id=">‍</p>`,
    publishedAt: "2025-01-01",
  },
  {
    id: "translating-promise-into-practice---clinical-applications-cros-and-the-future",
    slug: "translating-promise-into-practice---clinical-applications-cros-and-the-future",
    title: `Translating Promise into Practice – Clinical Applications, CROs, and the Future`,
    subtitle: `Harnessing Humanized Mouse Models Part 5`,
    description: `Part 5: Translating Promise into Practice – Clinical Applications, CROs, and the Future  Preclinical Disease Models That Deliver Better Predictive Power   In Part 4 we examined how organoids, chips,...`,
    category: "Industry Insights",
    relatedPage: "/custom-mouse-models",
    body: `<h3>Part 5: Translating Promise into Practice – Clinical Applications, CROs, and the Future<br>‍</strong></h3><h4>Preclinical Disease Models That Deliver Better Predictive Power</strong></h4><p>‍</strong>‍</p><p>research strategies, partnerships, and regulatory pathways</strong> that make the most of this ecosystem. Humanized mice still occupy the anchor position, since they provide the systemic validation that neither organoids, chips, nor AI can deliver alone. But their deployment requires addressing technical challenges, cost considerations, and regulatory expectations. We believe humanized mice, once a specialized resource, are a <strong>‍</p><h4>Standardization and Technical Challenges</strong></h4><p>Humanized mouse models have unquestionably advanced translational research, but several technical hurdles still limit their consistency and fidelity. Engraftment variability remains a major issue: even with standardized protocols, individual mice often show widely different levels of human cell engraftment and immune reconstitution [1,6]. Variability stems from factors like differences between human donors, conditioning regimens, and recipient mouse genetics. For example, using different human hematopoietic stem cell donors can lead to divergent engraftment rates and distinct immune cell population profiles in each mouse, complicating experimental reproducibility [2]. This means researchers must often use larger cohorts or more careful experimental designs to achieve statistical confidence.</p><p>Another fundamental challenge is incomplete humanization of the mouse. Current models typically replace or supplement certain systems (like the immune system or liver) with human cells, but large portions of the animal remain mouse. This incomplete humanization can impact results – the engrafted human cells are operating within a murine environment [1,5]. Key physiological factors (e.g. murine hormones, cytokines, and metabolic cues) differ from humans, potentially influencing how the human cells behave or respond to therapies. Even the immune-engrafted mice do not perfectly recapitulate a human immune system: many strains have weak human immune components and fail to generate certain human cells (for instance, robust human myeloid or NK cell compartments) due to the murine microenvironment [6]. Additionally, lymphoid architecture is often underdeveloped – humanized mice frequently lack fully functional lymph nodes or germinal centers in which human immune cells would normally interact [2]. These gaps mean that some human-specific aspects of immunity or disease (like complex T-cell interactions or antibody responses) are suboptimal in the models.</p><p>Graft-versus-host disease (GvHD) is another technical pitfall, especially as models achieve higher levels of human immune engraftment. Human T cells can recognize mouse tissues as “foreign,” leading to a deleterious immune attack on the host. In extreme cases, highly engrafted mice develop a lethal “wasting” syndrome – essentially a xenogeneic GvHD – that not only poses animal welfare concerns but also limits the duration of experiments [1]. Newer immunodeficient strains and the practice of HLA-matching human grafts to the host can mitigate the severity of GvHD, but even “mild” chronic GvHD or inflammatory stress may confound results [6]. Thus, investigators must balance achieving robust human immune reconstitution with controlling unwanted immune reactions.</p><p>Recognizing these issues, the community has pushed for standardization in humanized mouse research. A lack of uniform protocols and reporting standards has historically made it hard to compare results across labs – each group might use different source tissues, cell doses, conditioning regimens, and evaluation criteria [10]. To address this, international consortia have proposed standardized operating procedures and data reporting guidelines. Notably, in 2020 a coalition of experts introduced the “Minimal Information for Standardization of Humanized Mice” (MISHUM) guidelines, which define essential parameters to report (donor source, engraftment levels, mouse strain details, etc.) to improve rigor and reproducibility [10]. Dedicated humanized mouse CROs are also emerging as a way to maintain consistent production and quality control. By centralizing the generation of humanized mice, these specialized contractors can apply uniform engraftment techniques and quality metrics (such as flow cytometric chimerism assessments), ensuring that researchers receive mice with verified levels of human cells [5]. Such measures are already helping to reduce lab-to-lab variability and improve confidence in the models’ reliability.</p><p>Furthermore, advanced analytical technologies are being integrated to characterize humanized mice in greater depth. Techniques like single-cell RNA sequencing, high-dimensional flow cytometry, and sophisticated imaging can profile the human cells inside mice with unprecedented resolution [4]. These analyses serve as high-quality control – for instance, confirming that engrafted human immune cells differentiate appropriately and remain functional over time. They also reveal subtle differences (e.g. skewed cell subsets or activation states) that might arise due to the mouse environment, allowing researchers to account for those in their interpretations [6]. Encouragingly, studies are now pairing these state-of-the-art phenotyping methods with artificial intelligence (AI)–driven data analysis to extract patterns that might predict a model’s translational fidelity [4,11]. By systematically applying image analysis and machine learning to tissue scans or cell population data, scientists can better correlate what they see in the mouse with expected human outcomes, and flag discrepancies early. In summary, while humanized models still face engraftment inconsistency, partial human physiology, and immunological complications, concerted efforts in standardization and technology are actively addressing these challenges [11].</p><p><strong>‍</p><p>A prime example is the use of patient-derived xenografts (PDXs) in humanized mice. In a PDX, a tumor sample from a patient is implanted into an immunodeficient mouse. Traditionally PDX models lacked an immune system, but now researchers can engraft the same mouse with a human immune system (ideally from the same patient, creating an autologous match) to better mirror the patient’s tumor-immune interactions [8]. This allows multiple treatment regimens to be tested in vivo on the patient’s own cancer and immune cells. For instance, experimental drug combinations, immunotherapies, or cell therapies can be evaluated in these avatar mice to see which approach best shrinks the tumor or modulates the immune response [7]. The goal is to use these results to guide real-time clinical decisions – essentially, picking the therapy that showed the most promise in the mouse trial to treat the patient in the clinic.</p><p>Beyond oncology, personalized humanized models hold promise for immune therapies and vaccines. Scientists are exploring methods to engraft not just hematopoietic stem cells from patients but also mature immune cells into mice, alongside the patient’s tumor [7,9]. These autologous immune-PDX models create a human tumor microenvironment complete with the patient’s own immune repertoire. In such systems, one can test personalized cancer vaccines or trial an adoptive cell therapy (like CAR-T cells or TILs) against the patient’s tumor in vivo [7]. While true autologous “patient-on-a-mouse” models are still in early development, they represent a profound opportunity: to anticipate how an individual’s unique biology will respond to a therapy before administering it to that person.</p><p><strong>‍</p><h3>The Road Ahead</strong></h3><p>Having surveyed the current landscape, it’s clear that humanized mouse technology is continuously evolving. The next generation of models and methods promises to further enhance their precision and usefulness [4,11]. Key developments on the horizon include:</p><p><li>AI-Integrated Analytics:</strong> AI will mine complex datasets from humanized mice to uncover patterns tied to clinical outcomes, enabling faster go/no-go decisions, model refinement, and patient-response predictions [4].</li><li>CRISPR-Based Customization:</strong> CRISPR allows rapid creation of mice carrying patient-specific mutations or human variants, expanding models to humanize liver, neurons, or pancreatic islets [3].</li><li>Multi-Organ and Microphysiological Innovations:</strong> Humanized mice are becoming living microphysiological systems, combining organoids and grafts so one animal can host immune cells, liver, and tumors [11].</li><li>Improved Engraftment and Longevity:</strong> Next-gen strains extend lifespan and fidelity, with cytokine knock-ins, microbiome humanization, and tolerance protocols reducing graft failure and GvHD [6].</li></ul><p>Looking ahead, the convergence of these technologies – AI, CRISPR, organoid transplantation, and enhanced host engineering – promises a future where humanized mice are even more powerful and predictive [4,11].</p><h4>Conclusion</strong></h4><p>Across this five-part series, we have shown how humanized mice evolved from niche immunology tools into indispensable translational platforms [1,2]. They are not isolated competitors but central collaborators—anchoring an ecosystem that spans digital simulations, 3D tissues, microengineered organs, and advanced CRO-enabled pipelines. For translational research leaders, the imperative is clear: integration is not optional [5,9]. Those who embrace humanized models as a strategic core, while leveraging organoids, chips, and AI as complementary accelerants, will not only reduce attrition but also accelerate the arrival of therapies that truly benefit patients.</p><p>In conclusion, the road ahead for translational research is one where humanized models, advanced in vitro systems, and computational methods all work in concert [4,11]. Among these, humanized mice provide the irreplaceable context of a living organism, married with human biology – a combination that will drive discoveries not just in immunotherapy or oncology, but across infectious disease, regenerative medicine, and beyond [7,8]. We call on the biomedical community to fully integrate humanized mouse models into their toolkits. Those who do will be at the forefront of innovation, able to translate scientific promise into clinical practice faster and more successfully [10]. The future of medicine is knocking at the door, and it has the eyes of a mouse and the cells of a human. Opening that door widely will usher in the next generation of cures.</p>`,
    publishedAt: "2025-01-01",
  }
];

// Helper function to get article by slug
export function getArticleBySlug(slug: string): NewsletterArticle | undefined {
  return newsletterArticles.find(article => article.slug === slug);
}

// Helper function to get all slugs for static generation
export function getAllArticleSlugs(): string[] {
  return newsletterArticles.map(article => article.slug);
}

// Get featured articles (first 6)
export function getFeaturedArticles(): NewsletterArticle[] {
  return newsletterArticles.slice(0, 6);
}

// Get all unique categories
export function getAllCategories(): string[] {
  const categories = new Set(newsletterArticles.map(article => article.category));
  return ['All', ...Array.from(categories).sort()];
}

// Filter articles by category
export function getArticlesByCategory(category: string): NewsletterArticle[] {
  if (category === 'All') return newsletterArticles;
  return newsletterArticles.filter(article => article.category === category);
}
